

# Effects of Presenilin-1 Familial Alzheimer's Disease Mutations on $\gamma$ -Secretase Activation for Cleavage of Amyloid Precursor Protein

**Hung N. Do<sup>1,#</sup>, Sujan Devkota<sup>2,#</sup>, Apurba Bhattacharai<sup>1</sup>, Michael S. Wolfe<sup>2,\*</sup>, and Yinglong  
Miao<sup>1,\*</sup>**

<sup>1</sup>Center for Computational Biology and Department of Molecular Biosciences; <sup>2</sup>Department of  
Medicinal Chemistry, School of Pharmacy, University of Kansas, Lawrence, Kansas 66047

<sup>#</sup> These authors contributed equally to this work

\*To whom correspondence should be addressed: [mswolfe@ku.edu](mailto:mswolfe@ku.edu) and [miao@ku.edu](mailto:miao@ku.edu)

## Abstract

Presenilin-1 (PS1) is the catalytic subunit of  $\gamma$ -secretase which cleaves within the transmembrane domain of over 150 peptide substrates. Dominant missense mutations in PS1 cause early-onset familial Alzheimer's disease (FAD); however, the exact pathogenic mechanism remains unknown. Here we combined Gaussian-accelerated molecular dynamics (GaMD) simulations and biochemical experiments to determine the effects of six representative PS1 FAD mutations (P117L, I143T, L166P, G384A, L435F, and L286V) on the enzyme-substrate interactions between  $\gamma$ -secretase and amyloid precursor protein (APP). Biochemical experiments showed that all six PS1 FAD mutations rendered  $\gamma$ -secretase less active for the endoproteolytic ( $\epsilon$ ) cleavage of APP. Distinct low-energy conformational states were identified from the free energy profiles of wildtype and PS1 FAD-mutant  $\gamma$ -secretase. The P117L and L286V FAD mutants could still sample the "Active" state for substrate cleavage, but with noticeably reduced conformational space compared with the wildtype. The other mutants hardly visited the "Active" state. The PS1 FAD mutants were found to reduce  $\gamma$ -secretase proteolytic activity by hindering APP residue L49 from proper orientation in the active site and/or disrupting the distance between the catalytic aspartates. Therefore, our findings provide mechanistic insights into how PS1 FAD mutations affect structural dynamics and enzyme-substrate interactions of  $\gamma$ -secretase and APP.

**Keywords:**  $\gamma$ -secretase, presenilin-1, familial Alzheimer's disease, amyloid precursor protein, Gaussian accelerated molecular dynamics, free energy profiles.

## Introduction

$\gamma$ -Secretase is an intramembrane aspartyl protease complex composed of four components Nicastrin (NCT), Aph-1, Pen-2, and Presenilin-1 (PS1)<sup>1,2</sup>. PS1 is the catalytic component of  $\gamma$ -secretase, “the proteasome of the membrane”<sup>3</sup> which carries out intramembrane proteolysis of more than 150 peptide substrates<sup>4</sup>, including amyloid precursor protein (APP), via two conserved aspartates, D257 and D385<sup>5,6</sup>. Dominant missense mutations in PS1 can cause early-onset familial Alzheimer’s disease (FAD), a deadly chronic neurodegenerative disorder<sup>7</sup>. Although disease-causing PS1 mutations were first identified over 25 years ago, exact pathogenic mechanisms of FAD mutations remain unclear.

Two primary hypotheses have been proposed to explain the pathogenesis of FAD mutations. The loss-of-function hypothesis contends that PS1 FAD mutations reduce proteolytic activity of  $\gamma$ -secretase, which would impair cell signaling pathways by interfering with normal physiological functions of cleavage products, thereby leading to memory impairment and neurodegeneration<sup>8-10</sup>. In contrast, the gain-of-function hypothesis states that most FAD mutations increase the production of longer, more aggregation-prone A $\beta$  peptides, resulting in toxic oligomers that trigger Alzheimer’s disease (AD)<sup>10-12</sup>. However, these apparently opposing hypotheses can be reconciled by our experimental findings showing that PS1 FAD-mutant  $\gamma$ -secretase complexes are dramatically deficient in tricarboxypeptidase trimming of A $\beta$ 49 and A $\beta$ 48 initially produced through endoproteolytic ( $\epsilon$ ) cleavage<sup>13,14</sup>. Reduced trimming was also recently seen with 14 different FAD mutations in APP<sup>15</sup>. These reduced trimmings results in increased ratios of 42-residue A $\beta$  (A $\beta$ 42)—the primary component of AD cerebral plaques—to A $\beta$ 40<sup>14,16</sup> as well as increased proportions of longer intermediates A $\beta$ 45–A $\beta$ 49<sup>13,14</sup>. Recently, Sun et al. analyzed 138 pathogenic mutations in the PS1 of  $\gamma$ -secretase on the in vitro production of A $\beta$ 42

and A $\beta$ 40 peptides<sup>17</sup>. They found that ~90% of the mutations reduced the production of A $\beta$ 42 and A $\beta$ 40, and ~10% of these mutations decreased the A $\beta$ 42/A $\beta$ 40 ratio<sup>17</sup>. Moreover, Trambauer et al. studied seven A $\beta$ 43-producing PS1 FAD mutants, including M292D, L166P, V261F, Y256S, R278I, G382A, and L435F, and found that A $\beta$ 43 was produced in very high levels when the PS1 function was severely impaired<sup>18</sup>. Furthermore, alteration of enzyme-C99-substrate interactions were observed in all these mutants, regardless of their effects<sup>18</sup>.

Molecular dynamics (MD) is a powerful computational technique for simulating biomolecular dynamics at an atomistic level<sup>19</sup>. Kong et al.<sup>20</sup> performed the first atomistic simulation of isolated PS1 unit in 2015 and found that transmembrane domains (TM) 2, 6, and 9 were highly mobile<sup>21,22</sup>. In addition, only inactive distances between catalytic aspartates were sampled in the study because of the electrostatic repulsion caused by the negative charges of the two aspartates forming the active site<sup>20,21</sup>. The coarse-grained simulations of PS1 as part of the  $\gamma$ -secretase complex illustrated that PS1 was much more likely to be activated when either of the catalytic aspartates was protonated<sup>23</sup>. This finding was in good agreement with the proposed mechanism of aspartic proteases, which requires one of the catalytic aspartates to act as an acid<sup>24</sup>. Hitzenberger and Zacharias observed that the active state of PS1 remained stable even in the absence of a substrate as the direct hydrogen bond between protonated D257, D385, and a water bridge was sufficient to stabilize the active form<sup>21,25</sup>. Furthermore, the transition towards the active state of PS1 was found to involve TM1, TM6, TM7, TM8, and TM9<sup>21,25</sup>. In one recent study, conventional MD (cMD) has been applied to simulate the PS1 FAD mutations of E280A, G384A, A434C, and L435F, and APP FAD mutation of V717I. The simulations suggested that FAD mutations destabilize the enzyme-substrate complexes<sup>10</sup>. However, both catalytic aspartates were deprotonated in the system setups, likely resulting in repulsion between the negative charges. The

enzyme thus could not become active for substrate proteolysis during the simulations. In another study, free energy simulations have been carried out to examine the effects of selected PS1 FAD mutations, including L250S, S390I, L392V, L435S, P436S, and I439V<sup>26</sup>. Although different free energy profiles were revealed for the FAD mutants compared with the wildtype, these simulations were carried out in the absence of the substrate and the effects of FAD mutations on enzyme-substrate interactions could not be explored.

Gaussian accelerated molecular dynamics (GaMD) is an enhanced sampling technique that works by applying a harmonic boost potential to smooth biomolecular potential energy surface<sup>27</sup>. Since this boost potential exhibits a near Gaussian distribution, cumulant expansion to the second order (“Gaussian approximation”) can be applied to achieve proper energetic reweighting<sup>28</sup>. GaMD allows for simultaneous unconstrained enhanced sampling and free energy calculations of large biomolecules<sup>27</sup>. GaMD has been successfully demonstrated on enhanced sampling of ligand binding, protein folding, protein conformational, as well as protein-membrane, protein-protein, and protein-nucleic acid interactions<sup>29</sup>.

In 2020, Bhattacharai et al.<sup>30</sup> combined complementary GaMD simulations and biochemical experiments to investigate mechanisms of the  $\gamma$ -secretase activation and the  $\varepsilon$  cleavage of wildtype (WT) and FAD-mutant APP substrates. GaMD simulations captured spontaneous activation of  $\gamma$ -secretase: First, the protonated D257 formed a hydrogen bond with the backbone carboxyl group of APP residue L49. Then, one water molecule was recruited between the two catalytic aspartates through hydrogen bonds. In this way, the water molecule was activated for nucleophilic attack on the carbonyl carbon of APP residue L49 to carry out the  $\varepsilon$  cleavage. GaMD simulations also revealed that APP FAD mutations I45F and T48P preferred  $\varepsilon$  cleavage at the L49–V50 amide bond, whereas M51F shifted the  $\varepsilon$  cleavage site to the T48–L49 amide bond, being highly

consistent with experimental analyses of APP proteolytic products using mass spectrometry and western blotting<sup>1,30</sup>. Very recently, Pep-GaMD simulations were combined with further mass spectrometry and western blotting experiments to investigate tripeptide trimming of wildtype (WT) and FAD-mutant A $\beta$ 49 substrates by  $\gamma$ -secretase<sup>31</sup>. The Pep-GaMD simulations revealed remarkable structural rearrangements of both  $\gamma$ -secretase and A $\beta$ 49, where hydrogen-bonded catalytic aspartates and water were poised to carry out the  $\zeta$  cleavage of A $\beta$ 49 to A $\beta$ 46. Furthermore, the tripeptide trimming required inclusion of endoproteolytic coproduct APP intracellular domain (AICD) with a positively charged N-terminus. The simulation findings were also highly consistent with biochemical experimental data<sup>31,32</sup>.

In this work, we performed GaMD simulations and biochemical experiments in parallel to determine the effects of PS1 FAD mutations on  $\gamma$ -secretase activation for particularly the  $\epsilon$  cleavage of APP. We selected six PS1 FAD mutations to investigate based on early age of disease onset and their representative locations relative to the transmembrane domains (TM) of PS1, including P117L (hydrophobic loop 1), I143T (TM2), L166P (TM3), L286V (TM6, active site), G384A (TM7, active site), and L435F (TM9) (**Figure 1a**). Our GaMD simulations and biochemical experiments were largely consistent with each other and together provided important mechanistic insights into the effects of PS1 FAD mutations on structural dynamics and enzyme-substrate interactions of APP-bound  $\gamma$ -secretase.

## Results

### **Cleavage of APP by WT and PS1 FAD-mutant $\gamma$ -secretase in biochemical experiments**

To analyze the effects of six PS1 FAD mutations (P117L, I143T, L166P, G384A, L435F, and L286V) on the  $\epsilon$  cleavage of APP by  $\gamma$ -secretase, cleavage assays using purified WT and FAD

mutant  $\gamma$ -secretase were performed with purified, recombinant APP substrate C100-FLAG. Cleavage assay mixtures were subjected to quantitative western blotting using anti-FLAG primary antibodies. Known concentrations of C100-FLAG were run in parallel to make a calibration curve, where the band intensity was plotted versus the concentrations of FLAG-tagged C100, and a tight linear relationship was observed ( $R^2 = 0.99$ ) (**Figure 1b**). From this standard curve, the concentration of total AICD-FLAG products generated in the enzyme reaction mixtures were quantified. Quantification of the total AICD produced by FAD-mutant  $\gamma$ -secretase revealed significantly decreased  $\epsilon$  cleavage compared with WT  $\gamma$ -secretase (**Figure 1b**). In particular, the concentration of AICD-FLAG produced by WT  $\gamma$ -secretase was  $\sim 686 \pm 53$  nM. This concentration decreased to  $\sim 474 \pm 40$  nM with P117L,  $\sim 284 \pm 20$  nM with L286V,  $\sim 274 \pm 57$  nM with G384A,  $\sim 90 \pm 18$  nM with L166P,  $\sim 78 \pm 16$  nM with I143T, and  $\sim 64 \pm 17$  nM with L435F PS1 FAD-mutant  $\gamma$ -secretase, respectively (**Figure 1b**).

To further quantify the individual species of AICD, AICD generated in the cleavage assay were immunoprecipitated with anti-FLAG antibodies and monitored by matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS. The ratios of signal intensities corresponding to AICD 49-99 to AICD 50-99 were calculated and this ratio along with total AICD quantified with western blotting was used to calculate the concentration of AICD 49-99 and AICD 50-99. The ratios between AICD50-99 and AICD49-99 were  $\sim 1.1 \pm 0.1$  with WT  $\gamma$ -secretase,  $\sim 0.9 \pm 0.04$  with P117L,  $\sim 0.9 \pm 0.02$  with L286V,  $\sim 0.8 \pm 0.1$  with I143T,  $\sim 0.8 \pm 0.02$  with L166P,  $\sim 0.8 \pm 0.1$  with G384A, and  $\sim 0.7 \pm 0.1$  with L435F PS1 FAD mutants, respectively, as detected by MALDI-TOF MS (**Figure 1c**). Both species of AICD were significantly decreased for all the tested FAD mutants when compared to the WT  $\gamma$ -secretase (**Figure 1b**). In particular, the concentration of AICD 50-99 flag decreased from  $\sim 363 \pm 35$  nM with WT  $\gamma$ -secretase to  $\sim 213 \pm 15$  nM with

P117L,  $\sim 144 \pm 8$  nM with L286V,  $\sim 133 \pm 8$  nM with G384A,  $\sim 22 \pm 12$  nM with I143T,  $\sim 21 \pm 12$  nM with L166P, and  $\sim 17 \pm 12$  nM with L435F PS1 FAD mutant, respectively. The concentration of AICD 49-99 flag decreased from  $\sim 305 \pm 28$  nM with WT  $\gamma$ -secretase to  $\sim 222 \pm 16$  nM with P117L,  $\sim 157 \pm 9$  nM with L286V and G384A,  $\sim 26 \pm 16$  nM with L166P,  $\sim 26 \pm 14$  nM with I143T, and  $\sim 22 \pm 16$  nM with L435F PS1 FAD mutant, respectively (**Figure 1b**). Since the average concentrations of AICD 50-99 and AICD 49-99 were relatively close, there was only very subtle shift in the  $\epsilon$  cleavage of APP from the 49<sup>th</sup> to the 48<sup>th</sup> residue for all FAD mutants.

#### **Free energy profiles of the $\epsilon$ cleavage of APP by WT and PS1 FAD-mutant $\gamma$ -secretase**

In parallel with biochemical experiments, all-atom dual-boost GaMD simulations were carried out on WT, P117L, I143T, L166P, G384A, L435F, and L286V PS1 FAD-mutant  $\gamma$ -secretase bound by APP (**Supplementary Table 1**). GaMD simulations recorded similar averages and standard deviations of the boost potentials among different systems, i.e.,  $13.5 \pm 4.3$  kcal/mol for the WT,  $11.3 \pm 4.0$  kcal/mol for P117L,  $14.0 \pm 4.4$  kcal/mol for I143T,  $14.8 \pm 4.5$  kcal/mol for L166P,  $13.8 \pm 4.4$  kcal/mol for G384A,  $14.0 \pm 4.4$  kcal/mol for L435F, and  $14.1 \pm 4.1$  kcal/mol for L286V PS1 FAD mutant  $\gamma$ -secretase, respectively (**Supplementary Table 1**). In this study, we chose to protonate D385 as its pKa value was calculated to be higher than that of D257 (8.8 to 8.0, respectively) (**Supplementary Table 2**). In addition, the protonation of one catalytic aspartate (D385) allowed us to obtain comparable D257-D385 distances in our GaMD simulations with the available PDB structures of  $\gamma$ -secretase (**Supplementary Table 3**). In particular, distances between the C $\gamma$  atoms of catalytic aspartates D257-D385 calculated from GaMD simulations were  $7.3 \pm 1.9$  Å for WT,  $7.6 \pm 1.1$  Å for P117L,  $8.2 \pm 1.6$  Å for I143T,  $8.7 \pm 1.0$  Å for L166P,  $8.1 \pm 1.2$  Å for G384A,  $9.1 \pm 1.2$  Å for L435F, and  $7.4 \pm 1.0$  Å for L286V PS1 FAD mutant  $\gamma$ -secretase

(**Supplementary Figures 1–4**). Meanwhile, the lowest D257-D385 distance could get to ~3.9 Å in the 5FN2<sup>33</sup> PDB structure, while most of the experimental D257-D385 and D257-A385 (in the 6IDF and 6IYC PDB) distances were between ~5 Å and ~9 Å<sup>33–37</sup>. The highest D257-D385 distance was ~11.5 Å, observed in the 5FN4<sup>33</sup> PDB structure (**Supplementary Table 3**). The  $\varepsilon$ -cleavage of APP by  $\gamma$ -secretase can only be carried out when the two PS1 catalytic aspartates are at a suitable distance so that a nucleophilic water molecule can be recruited for the proteolytic reaction through water-bridged hydrogen bonding with the two aspartates<sup>5,26,30</sup>. Furthermore, the carbonyl group at the cleavage site on APP (residue L49) would form another hydrogen bond between the carbonyl oxygen and protonated carboxylic side chain of catalytic residue D385 in PS1 for proteolysis<sup>5,26,30</sup>. Therefore, the distance between the C $\gamma$  atoms of catalytic aspartates D257 and D385 in PS1 and the distance between PS1 residue D385 (protonated oxygen) and APP residue L49 (carbonyl oxygen) were calculated from the GaMD simulations and plotted in **Supplementary Figures 1–4**. They were used as reaction coordinates to calculate two-dimensional (2D) potential mean force (PMF) free energy profiles to characterize the effects of PS1 FAD mutations on  $\gamma$ -secretase activation for  $\varepsilon$  cleavage of APP (**Figure 1**). Overall, the WT  $\gamma$ -secretase sampled noticeably larger conformational space than the PS1 FAD mutants.

A total of seven different low-energy conformational states were identified from free energy profiles of the WT and six PS1 FAD mutants of  $\gamma$ -secretase bound by APP, namely “Active”, “Inhibited”, and five intermediate states “I1”, “I2”, “I3”, “I4”, and “I5” (**Figure 1**). The “Active” state was observed in free energy profiles of the WT, P117L, and L286V PS1 FAD-mutant  $\gamma$ -secretase (**Figure 1d, 1e, and 1j**). In this state, the catalytic aspartates D257 and D385 in PS1 were ~7–9.5 Å apart and residue D385 formed a hydrogen bond with APP residue L49 at

~2.5–3 Å distance. At ~7–8 Å distance between the Cy atoms, the two catalytic aspartates could recruit a water molecule through hydrogen bonds, poised for the  $\epsilon$  cleavage of APP.

The “Inhibited” and “I1” low-energy conformational states were only observed in the free energy profile of WT  $\gamma$ -secretase (**Figure 1d**). In the “Inhibited” state, the distance between catalytic aspartates D257 and D385 reduced to ~4 Å, whereas the distance between PS1 residue D385 and APP residue L49 increased to ~10–13 Å. In the “I1” state, the D257–D385 and D385–L49 distances became ~8–10 Å and ~7.5–9.5 Å, respectively.

The “I2” low-energy conformational state was observed in the free energy profiles of most of the PS1 FAD mutants, with the only exception of L435F (**Figure 1e–1j**). In this low-energy state, the distance between PS1 residues D257 and D385 decreased to ~6–7 Å, while the distance between PS1 residue D385 and APP residue L49 varies between PS1 FAD mutations in a range of ~3–7 Å.

The “I3” low-energy conformational state was identified from the free energy profiles of three PS1 FAD mutations, including I143T (**Figure 1f**), L166P (**Figure 1g**), and G384A (**Figure 1h**). In this state, the distance between the two catalytic aspartates D257 and D385 ranged from ~8–10 Å, while the distance between D385 and L49 of APP was ~4–7 Å.

The “I4” low-energy state was only observed in the free energy profile of one PS1 FAD mutant, I143T (**Figure 1f**). In this state, the distance between PS1 residues D257 and D385 was ~5–6 Å in the range between the “Inhibited” and “Active” states. However, the PS1 residue D385 and APP residue L49 was far apart, with a distance of ~10–11 Å.

The “I5” low-energy state was observed in the free energy profile of two PS1 FAD mutants, including I143T (**Figure 1f**) and L166P (**Figure 1g**). The distance between PS1 residues D257 and D385 centered around ~8.5–10 Å, while the distance between PS1 residue D385 and APP

residue L49 ranged from  $\sim$ 2.5–4 Å in the “I5” state. The representative structures of all low-energy conformational states of APP-bound  $\gamma$ -secretase were provided in **Supplementary Data 1**.

### “Active” low-energy conformational state of $\gamma$ -secretase bound by APP

The “Active” low-energy conformational state was identified in the WT, P117L, and L286V  $\gamma$ -secretase (**Figure 1d**, **1e**, and **1j**). This low-energy conformational state was characterized by the D257–D385 distance of  $\sim$ 7–9.5 Å and D385–L49 distance of  $\sim$ 2.5–3 Å. Representative PS1 and APP conformations of “Active” WT, P117L, and L286V  $\gamma$ -secretase obtained from structural clustering of their GaMD simulation snapshots using CPPTRAJ<sup>38</sup> were aligned for comparison in **Figure 2**. The  $C_\alpha$ -RMSD of PS1 and APP of “Active” L286V and P117L relative to WT were  $\sim$ 1.7 and  $\sim$ 1.7 Å, respectively, illustrating the similarity between these conformations. However, it is worth noting that the intracellular ends of TM2, TM3, TM6a, and TM8 moved inwards in the L286V and P117L PS1 mutants compared to WT  $\gamma$ -secretase (**Figure 2a**).

The active site in the WT, P117L, and L286V PS1 was compared in **Figure 2b**. Overall, PS1 residues D257 and D385 and APP residue L49 were well aligned among the three simulation systems. The distances between the  $C_\gamma$  atoms of residues D257 and D385 in WT, L286V, and P117L PS1 were  $\sim$ 7.0,  $\sim$ 7.0, and  $\sim$ 7.4 Å, respectively. These distances were all suitable for the catalytic aspartates to activate nucleophilic water to carry out the proteolytic reaction. Notably, the side chains of D257 and D385 could rotate in the simulation systems (**Figure 2b**). The protonated oxygen of D385 formed a hydrogen bond with the backbone carbonyl oxygen of APP residue L49 in the WT, L286V, and P117L PS1 systems with distances of  $\sim$ 3.0,  $\sim$ 2.9,  $\sim$ 2.7 Å, respectively.

Next, we examined the secondary structures of the PS1 and substrate near the active site in **Figure 2c** as they appeared different across the three systems. In the “Active” WT low-energy

conformational state, while the  $\beta$ 1 domain (connected to TM6a) remained unstructured, the  $\beta$ 2 strand (connected to TM7) formed a hybrid  $\beta$ -sheet with the C-terminal  $\beta$ 3 strand of APP, between PS1 residues V379–L381 and APP residues M51–K53. In the “Active” L286V low-energy conformational state, antiparallel  $\beta$ -strands were formed between the  $\beta$ 1,  $\beta$ 2, and  $\beta$ 3 domains, involving PS1 residues Y288–S290 and G378–L381 and APP residues M51–K53. In the “Active” low state of P117L PS1 FAD mutant, the antiparallel  $\beta$ -strands were formed between the  $\beta$ 2 domain and  $\beta$ 3 APP C-terminus, involving PS1 residues R377–K380 and APP residues L52–K54.

The helical domain of APP tilted in the P117L and L286V PS1 by ~9 and 34 degrees, respectively, compared to that in WT PS1 (**Figure 2d**). Meanwhile, the extracellular end of the APP helical domain in the L286V and P117L PS1 FAD mutants moved by ~6.8 and ~15.7 Å, respectively. The length of the APP helical domain also decreased from ~28.1 Å in the WT PS1 to ~24.5 Å and ~22.5 Å in the L286V and P117L mutants, respectively.

The locations of P1', P2', and P3' residues and corresponding S1', S2', and S3' subpockets in the “Active” WT, L286V, and P117L PS1 FAD-mutant  $\gamma$ -secretase were compared in **Figure 2e**. Here, P1', P2', and P3' referred to APP residues that were one, two, and three residues away downwards, respectively, from the APP cleavage side residue L49 (i.e., V50, M51, and L52). The corresponding S1', S2', and S3' subpockets consisted of residues that were within 5 Å of APP substrate residues P1' V50, P2' M51, and P3' L52. The RMSD of the  $C_{\alpha}$  atoms in the P1', P2', and P3' residues of APP in the L286V PS1 mutant was ~0.1 Å relative to that in the WT PS1. On the other hand, RMSD of the  $C_{\alpha}$  atoms in the P1', P2', and P3' residues of APP in the P117L PS1 mutant increased to ~0.2 Å. In addition, RMSD of the  $C_{\alpha}$  atoms in the corresponding S1', S2', and S3' subpockets relative to WT PS1 was lower in the L286V than in the P117L mutant, with respective values of ~1.6 Å compared to ~3.7 Å. The full lists of residues constituting the S1', S2', and S3' subpockets are provided in **Table 2**.

and S3' subpockets in the three systems can be found in **Supplementary Table 4**. It is worth noting that the total numbers of residues constituting the S1', S2', S3' subpockets in the L286V and P117L PS1 mutants were both 36 and larger than that in the WT PS1, which was 23 (**Supplementary Table 4**).

### **Intermediate low-energy conformational states of $\gamma$ -secretase bound by APP**

Besides the “Active” state, six other intermediate low-energy conformational states were identified from the free energy profiles of WT and PS1 FAD-mutant  $\gamma$ -secretase, including “Inhibited”, “I1”, “I2”, “I3”, “I4”, and “I5”. Representative PS1 and APP conformations of the intermediate low-energy states were compared to the “Active” state of WT PS1 in **Figures 3–4** and **Supplementary Figures 5–8**.

Different active site conformations in the intermediate low-energy states were compared to the “Active” state of WT PS1 in **Figure 3**. In the “Inhibited” low-energy state, the distance between the two catalytic aspartates D257 and D385 in PS1 decreased from  $\sim 7.0$  Å to  $\sim 4.1$  Å, whereas the distance between residue D385 and APP residue L49 increased from  $\sim 3.0$  Å to  $\sim 12.5$  Å (**Figure 3a**). The two catalytic aspartates moved towards each other, resulting in the formation of a hydrogen bond between the proton of D385 and carbonyl oxygen of D257. Meanwhile, residue L49 in APP moved downwards by  $\sim 6$  Å, providing room for the formation of D257–D385 hydrogen bond (**Figure 3a**). In the “I1” low-energy state, the PS1 TM6 and APP  $\beta$ 3 strand moved away from PS1 TM7, which increased the D257–D385 and D385–L49 distances to  $\sim 8.6$  and  $\sim 8.4$  Å, respectively (**Figure 3b**). The “I2” state was similar to “I1”, except that TM7 moved inwards relative to the “Active” state in WT PS1, reducing both the D257–D385 and D385–L49 distances to  $\sim 6.5$  Å (**Figure 3c**). In the “I3” state, TM6 moved slightly outwards and APP substrate moved

slightly upwards relative to the “Active” WT conformation. These movements increased the distance between PS1 residues D257 and D385 to  $\sim 9$  Å and reduced the distance between PS1 residue D385 and APP residue L49 to  $\sim 6$  Å (**Figure 3d**). The “I4” was the only intermediate conformational state where TM6 shifted inwards relative to the “Active” WT, reducing the D257–D385 distance to  $\sim 6.2$  Å. In addition, APP residue L49 moved downwards for  $\sim 6$  Å, increasing the D385–L49 distance to  $\sim 11.5$  Å (**Figure 3e**). Notably, the antiparallel  $\beta$  strands between the  $\beta$ 2 domain near PS1 TM7 and the  $\beta$ 3 domain in the APP C-terminus were maintained in all but two of the intermediate low-energy states (i.e., “Inhibited” and “I4”). Furthermore, the backbone carbonyl group of APP residue L49 pointed towards D257 instead of the protonated D385 in three of the intermediate states (“I1”, “I2”, and “I3”).

In the “I5” low-energy conformational state, the protonated oxygen atom of D385 in PS1 formed a hydrogen bond with APP residue L49 at a  $\sim 2.9$  Å distance. However, the distance between PS1 residues D257 and D385 increased to  $\sim 8.5$  Å due to a helical stretch around residue Y256 in TM6 (**Figure 3f**). The stretch moved residue D257 downwards relative to the “Active” WT and increased the D257–D385 distance out of the  $\sim 7$ – $8$  Å range required for activation of  $\gamma$ -secretase. In fact, with  $\sim 7$  Å distance between D257–D385, the active site in the “Active” WT conformational state was properly poised for the two catalytic aspartates to recruit a water molecule. The water molecule was made nucleophilic and properly oriented to carry out the  $\varepsilon$  cleavage of APP residue L49 through the hydrogen bonds formed with the carboxylic side chains of residues D257 and D385 (**Figure 4a**). To further examine the water dynamics during  $\gamma$ -secretase activation for  $\varepsilon$ -cleavage of APP, we reproduced a 100ns GaMD simulation of the “Active” WT  $\gamma$ -secretase, starting from the 1200ns checkpoint of Sim1, and saved the coordinates of not only proteins and substrates but also lipids, ions, and water molecules (**Supplementary Figure 9**). The time courses

of the D257-D385 and D385-L49 distances were calculated and shown in **Supplementary Figure 9a**. Upon the formation of the D385-L49 hydrogen bond at  $\sim 3\text{\AA}$  distance while the PS1 residues D257 and D385 maintained  $\sim 6\text{-}8\text{\AA}$  distance, a water molecule was recruited (**Supplementary Figure 9b**) and trapped between the two catalytic aspartates (**Supplementary Figure 9c**) to carry out the proteolytic reaction in the “Active” conformation. This has also been observed in our previous study<sup>30</sup>. At the D257–D385 distance of  $\sim 8.5\text{ \AA}$  in the “I5” state, the active site was so “open” that no water molecule could be properly stabilized between the catalytic aspartates for the proteolytic reaction (**Figure 4b**). Furthermore, the locations of P1’, P2’, and P3’ residues and corresponding S1’, S2’, and S3’ subpockets were compared between the “Active” and “I5” low-energy conformational states (**Figure 4c**). Here, the  $C_{\alpha}$ -RMSD of P1’, P2’, and P3’ residues of APP in the “I5” low-energy conformation relative to “Active” WT was  $\sim 0.24\text{ \AA}$ , and the  $C_{\alpha}$ -RMSD of S1’, S2’, and S3’ subpockets was  $\sim 0.91\text{ \AA}$ . The total number of residues constituting the S1’, S2’, and S3’ subpockets of the “I5” low-energy conformational state (24) was similar to that of “Active” WT conformation (23) (**Supplementary Table 4**).

We compared the entire PS1 subunit bound to APP in the intermediate low-energy states to the “Active” WT state in **Supplementary Figures 5–8**. A number of notable differences were identified in the APP substrate (**Supplementary Figure 6**), the  $\beta 1$ ,  $\beta 2$ , and  $\beta 3$  domains (**Supplementary Figure 7**), and PS1 TM8 (**Supplementary Figure 8**). First, the APP helical domain tilted in all the intermediate conformations relative to the “Active” WT conformation, with the largest tilts observed in the “Inhibited” and “I1”, and the smallest tilt in the “I5” state (**Supplementary Figure 6**). Compared to the “Active” WT conformation, the extracellular end of APP moved by  $\sim 11.7\text{ \AA}$  in the “Inhibited”,  $\sim 11.8\text{ \AA}$  in the “I1”,  $\sim 9.3\text{ \AA}$  in the “I2”,  $\sim 10.2\text{ \AA}$  in the “I3”,  $\sim 11.2\text{ \AA}$  in the “I4”, and  $\sim 6.9\text{ \AA}$  in the “I5”, with respective tilt angles of  $\sim 24^\circ$ ,  $\sim 25^\circ$ ,  $\sim 17^\circ$ ,

$\sim 14^\circ$ ,  $\sim 16^\circ$ , and  $\sim 14^\circ$  (**Supplementary Figure 6**). The length of APP helical domain also changed  $\sim 28.1$  Å in the “Active” WT state to different values in the intermediate conformations. It decreased to  $\sim 27.3$  Å in the “Inhibited”,  $\sim 25.8$  Å in the “I1”, and  $\sim 6.9$  Å in the “I4”, while increased to  $\sim 30.7$  Å in the “I2”,  $\sim 30.1$  Å in the “I3”, and  $\sim 29.0$  Å in the “I5”.

Second, the  $\beta 1$ ,  $\beta 2$ , and  $\beta 3$  domains (connected to TM6a, TM7, and APP, respectively) also varied in their conformations in the intermediate low-energy conformational states relative to the “Active” WT conformation (**Supplementary Figure 7**). In the “Inhibited” and “I4” states, the  $\beta 3$  domain lost its  $\beta$ -strand secondary structure as it moved away from  $\beta 2$ , while the  $\beta 2$  formed anti-parallel  $\beta$ -strands with  $\beta 1$ . (**Supplementary Figure 7a** and **7e**). In the “I1”, “I3”, and “I5” states, the  $\beta 1$ ,  $\beta 2$ , and  $\beta 3$  domains formed antiparallel  $\beta$ -sheets with one another (**Supplementary Figure 7b**, **7d**, and **7f**). Notably, the  $\beta 2$  and  $\beta 3$  strands extended in the “I1” state, involving residues R377–G378 near TM7 and K54 of APP. In the “I2” state, the secondary structures of the  $\beta$  domains were similar to those in the “Active” WT conformation (**Supplementary Figure 7c**). Furthermore, TM6a tilted noticeably in the “I1”, “I2”, and “I3” states compared to “Active” WT, with the largest tilt observed in the “I3” conformation (**Supplementary Figure 7b**, **7c**, and **7d**).

Third, the intracellular end of TM8, which lies at the interface of PS1 and APH-1 subunits, all moved away from the PS1 TM bundle towards the APH-1 subunit in the intermediate low-energy conformations (**Supplementary Figures 5** and **8**). Relative to the “Active” WT conformation, the TM8 intracellular end moved by  $\sim 7.5$  Å in the “Inhibited”,  $\sim 5.9$  Å in the “I1”,  $\sim 7.0$  Å in the “I2”,  $\sim 7.4$  Å in the “I3”,  $\sim 7.7$  Å in the “I4”, and  $\sim 5.0$  Å in the “I5” state. In addition, the helical domain of TM8 in the “I2” conformation was distorted at residue L423 (**Supplementary Figure 8c**).

## Secondary structures of APP substrate in WT and PS1 FAD-mutant $\gamma$ -secretase

Representative time courses of APP secondary structures for the WT and PS1 FAD-mutant  $\gamma$ -secretase were shown in **Figure 5**, while time courses of APP secondary structure from the remaining GaMD simulations were plotted in **Supplementary Figures 10–13**. Overall, APP secondary structures in WT PS1 changed notably to those in PS1 FAD mutants, even for those whose proteolytic activity reduced only slightly, such as P117L. In the WT  $\gamma$ -secretase, residues K28–V46 were mostly helical, with few fluctuations to become 3-10-helices at residues A42–V46, in the representative Sim1, where the “Active” conformation was observed (**Figure 5a**). Notably, for  $\sim$ 50 ns between 350–400 ns, residues V44–I45 turned 3-10-helical for the first half. The APP C-terminus was extended  $\beta$ -sheets during parts of Sim1. In particular, residues I47–L50 incidentally turned 3-10-helices, whereas residues M51–K53 were mostly extended  $\beta$ -sheets in Sim1 (**Figure 5a**). The time courses of APP secondary structures in Sim2 and Sim3 of WT  $\gamma$ -secretase were shown in **Supplementary Figure 10**.

In the P117L PS1 FAD mutant  $\gamma$ -secretase, APP secondary structures were similar between the representative (Sim1) (**Figure 5b**) and other simulations (**Supplementary Figure 11a-b**). First, the N-terminus of APP, involving residues V18–G29, could be helical. Residues V18–E22, specifically, adopted 3-10-helices in Sim1 (**Figure 5b**) or  $\alpha$ -helix conformation during Sim2 and Sim3 (**Supplementary Figure 11a-b**). The length of APP helical domain in the P117L FAD mutant remained similar to that in the WT PS1, covering residues A30–V46. However, the APP C-terminus was  $\beta$ -strand in residues M51–K54 (**Figure 5b** and **Supplementary Figure 11**).

In the I143T PS1 mutant, the representative time course of APP secondary structures (Sim1) showed a slight increase in the helical length involving residues K28–L49 compared to K28–V46 of APP in the WT PS1 (**Figure 5c**). Compared to other systems, APP residue A42 was

solely  $\alpha$ -helical in this mutant, while residue I47 could be either helical or turned (Figure 5c and Supplementary Figure 12). Furthermore, only in Sim2 were residues M51–K53 observed as extended  $\beta$ -sheet for most of the simulation (Supplementary Figure 12c). In Sim1 and Sim3, this portion of APP C-terminus occasionally became 3-10-helices between residues L52–K54 observed during ~450–610 ns and ~820–1200 ns of Sim1 (Figure 5c).

In the L166P PS1 mutant, the average APP helical length included residues K28–I47 (Figure 5d and Supplementary Figure 13a–b). Furthermore, residues T43–V45 could be 3-10-helices and turns. Here, residues L17–N27 at the N-terminus of APP were mostly unstructured or turns, with some fluctuations to 3-10-helices, while residues M51–K53 at the C-terminus of APP could be mostly extended  $\beta$ -sheets (Figure 5d and Supplementary Figure 13).

The secondary structures of APP in the G384A PS1 mutant were mostly similar to other simulation systems (Figure 5e and Supplementary Figure 12). However, two notable differences could be identified from the simulation time courses. First, residues M51–K53 in the APP C-terminus were mostly turns or unstructured across all three simulations. Second, residues I47–L49 mostly adopted the 3-10-helical conformation, unlike other simulation systems where  $\alpha$ -helix were the preferred conformations for this region (Figure 5e and Supplementary Figure 12).

For the remaining PS1 FAD mutants, including L435F (Figure 5f) and L286V (Figure 5g), the APP secondary structures were almost identical to those in certain PS1 FAD mutants as described above. In particular, the time courses of the L435F FAD mutant (Figures 5f and Supplementary Figure 13c–d) were similar to those of L166P (Supplementary Figure 13a) and G384A (Figure 5e and Supplementary Figure 12c–d) PS1 FAD mutants. For L286V, the secondary structures of APP were comparable to those in the P117L PS1 mutant, being consistent

with the high similarity between the free energy profiles of these two systems (**Figures 1, 5, and Supplementary Figure 11**).

## Discussion

In this work, we have presented the first dynamic models for cleavage of amyloid precursor protein (APP) by PS1 FAD mutants of  $\gamma$ -secretase, which were consistent with mass spectrometry (MS) and western blotting biochemical experiments. Through the quantifications of the total AICD species produced by WT and PS1 FAD mutant  $\gamma$ -secretase, our biochemical experiments revealed significantly decreased  $\varepsilon$ -cleavages of APP by the PS1 FAD mutants compared to WT  $\gamma$ -secretase<sup>39-41</sup>. Since the PS1 FAD mutants mostly reduced  $\varepsilon$ -cleavage efficiency, the catalytic efficiency should be reduced, which means lower values of  $k_{cat}/K_M$ . The reason the experimental results specifically show reduction in  $k_{cat}$  is that they are performed under conditions of substrate saturation. Under these conditions the rate is only determined by the  $k_{cat}$  and the concentration of enzyme, the latter which is kept constant. Therefore, a reduced rate of AICD product formation is due to a corresponding decrease in the  $k_{cat}$ . GaMD simulations were carried out in parallel to explain the biochemical results in atomistic details. From the 2D free profiles calculated from GaMD simulations, important low-energy conformational states were identified for each simulation system of  $\gamma$ -secretase. The free energy landscapes and low-energy conformational states were explored in detail, which allowed us to deduce the effects of PS1 FAD mutants on the proteolytic activity of  $\gamma$ -secretase. Here, our main conclusion was that the PS1 FAD mutant  $\gamma$ -secretase stabilized the active sites of the enzyme-substrate complexes, which was distinctly different from previous studies, which suggested that PS1 FAD mutants destabilized the enzyme-substrate complexes, causing the earlier releases of longer A $\beta$  peptides<sup>10,22,42-45</sup>.

Our experimental method has already been validated in one other recent study<sup>15</sup>. In that study, we quantified all proteolytic events by  $\gamma$ -secretase on C100-Flag substrate with WT and 14 FAD-mutant substrates. For these 15 variants of C100-Flag, the quantification of AICD-Flag using the western blotting method (with C100-Flag itself used as the standard) gave results that were highly consistent with those from LC-MS/MS quantification of small peptide carboxypeptidase coproducts<sup>15</sup>. In deducing the production of all A $\beta$  variants from these data, we found that total AICD equaled total A $\beta$  in all cases. Moreover, the sums of A $\beta$  peptides produced along the A $\beta$ 40-producing pathway from A $\beta$ 49 and along the A $\beta$ 42-producing pathway from A $\beta$ 48 were equivalent to their corresponding AICD products (AICD50-99 and AICD49-99, respectively)<sup>15</sup>. If the quantification of AICD-Flag using C100-Flag as the standard were inaccurate, such close agreement between AICD and A $\beta$  products would not have been observed. Moreover, while the AICD bands produced from I143T, L166P and L435F were extremely faint, they were visible and within range of the standard curve (stronger than the band of the lowest concentration standard) (**Figure 1b**).

The experimental effects seen on AICD production with the specific PS1 mutations under study here have also been reported by other groups<sup>13,17,46-48</sup>. According to Chávez-Gutiérrez et al., AICD production was reduced by the G384A, L166P, and I143T PS1 FAD mutants<sup>49</sup>. Severely compromised  $\gamma$ -secretase activity with the L435F PS1 FAD mutant has been previously reported by several groups<sup>17,46-48</sup>. For the L286V PS1 FAD mutant, we are only aware of our own previous report on its effect on  $\gamma$  cleavage to AICD<sup>13</sup>. In that report, we did not see decreased AICD production vis-à-vis WT enzyme; however,  $\gamma$ -secretase components were overexpressed in Chinese hamster ovary (CHO) cells with endogenous enzyme present, and assays were conducted using isolated membranes, not purified enzyme complexes. Therefore, we favor the results from

our current study, which were obtained with purified enzyme and more rigorous quantification of AICD using a standard curve. For the P117L PS1 FAD mutant, we are unaware of any reports on the overall proteolytic activity, only A $\beta$ 42/40 ratios.

We performed four additional 1.5 $\mu$ s cMD simulations on each of four representative APP-bound  $\gamma$ -secretase systems, including the WT and the P117L, I143T, and L166P PS1 FAD mutants. The time courses of the D257-D385, D385-V50, D385-L49, and D385-T48 distances calculated from the cMD simulations were plotted in **Supplementary Figure 14**. 2D free energy profiles of the (D257-D385, D385-L49), (D257-D385, D385-V50), or (D257-D385, D385-T48) distances (**Supplementary Figure 15**) were calculated and compared with those from GaMD simulations (**Figure 1** and **Supplementary Figure 16**). For both the cMD and GaMD simulations, the low-energy conformational states calculated from both the D385-V50 and D385-T48 distances matched those calculated from the D385-L49 distances. Moreover, GaMD sampled larger conformational space than the cMD simulations and uncovered additional low-energy conformational states in the WT, I143T, and L166P FAD mutant  $\gamma$ -secretase systems (**Figure 1** and **Supplementary Figure 16**). In particular, the WT, I143T, and L166P simulation systems visited two (“Inhibited” and “I1”), one (“I4”), and one (“I3”) additional low-energy conformational states in the GaMD simulations than in the cMD simulations, respectively (**Figure 1d,f,g** and **Supplementary Figure 15a,c,d**). In the P117L simulation system, both GaMD and cMD uncovered two low-energy conformational states, i.e., the “Active” and “I2” (**Figure 1e** and **Supplementary Figure 15b**). These findings demonstrated the enhanced sampling power of GaMD in simulations of large biomolecules such as  $\gamma$ -secretase.

GaMD simulations of WT  $\gamma$ -secretase for  $\epsilon$  cleavage of APP led to three primary low-energy conformational states, including “Inhibited”, “I1”, and “Active” (**Figure 1d**). In the

“Inhibited” low-energy conformation, the two catalytic aspartates D257 and D385 formed a hydrogen bond with each other<sup>50</sup>, precluding their interaction with and activation of a water molecule, while APP residue L49 was located downstream and far away (**Figure 3a**). In the “I1” low-energy conformational state, the active site opened up as residues D257 and D385 moved away from one another, while APP residue L49 moved upwards compared to the “Inhibited” low-energy conformation (**Figure 3b**). As the APP substrate was properly located inside the active site, its  $\beta$ 3 strand (involving APP residues M51–K53) was formed through the hydrogen bonds with the  $\beta$ 2 strand connected to PS1 TM7 (involving PS1 residues V379–L381)<sup>50</sup>. This finding was highly consistent with previous simulation studies, in which the repeated formations of  $\beta$ -strands in several solvent-exposed regions of presenilin were observed<sup>22,43,51,52</sup>. Afterwards, the catalytic aspartates D257 and D385 drew closer to each other, at a  $\sim$ 7–8 Å distance in the “Active” conformation, to recruit a water molecule poised for the proteolytic reaction (**Figure 4a**). The water molecule was made nucleophilic and properly oriented through the hydrogen bonds with the carboxylic side chains of D257 and D385, while the backbone carbonyl of APP residue L49 was made more electrophilic through a hydrogen bond formed with the protonated oxygen atom of residue D385 (**Figures 2b** and **4a**). With all the proper conditions met,  $\gamma$ -secretase activation for  $\epsilon$  cleavage of APP was carried out in the “Active” low-energy conformational state (**Figure 6b**). This finding agrees well with our previous study<sup>30</sup> even though a different aspartate in PS1 (D385) was protonated because of the higher pKa value calculated by PROPKA3<sup>53,54</sup>. Furthermore, given the locations of the low-energy conformational states in the WT free energy profile (**Figure 1d**), it was plausible that transitions could take place between the “Inhibited” and “I1” as well as “I1” and “Active” conformations.

The effects of PS1 FAD mutants on  $\gamma$ -secretase activation for  $\epsilon$  cleavage of APP could be deduced from the respective 2D free energy profiles, low-energy conformational states associated with each mutant, and changes in the APP substrate. As described in the Results section, the conformational space of WT  $\gamma$ -secretase (**Figure 1d**) was noticeably larger compared to the PS1 FAD mutants, especially in the D385–L49 distance. In particular, the distance between PS1 residue D385 and APP residue L49 could range from  $\sim$ 2–15 Å, and the distance between PS1 residues D257 and D385 was between  $\sim$ 3 and  $\sim$ 13 Å in WT  $\gamma$ -secretase. When we compared the “Active” low-energy conformations among WT, L286V, and P117L PS1 FAD mutants, TM2, TM3, TM6a, and TM8 all moved inwards in the two FAD mutants compared to WT  $\gamma$ -secretase (**Figure 2a**). Therefore, the active site of WT  $\gamma$ -secretase appeared more flexible than the PS1 FAD mutants. This was further reinforced by the finding that fewer PS1 residues constituted the S1’, S2’, and S3’ subpockets of the “Active” WT compared to “Active” P117L and L286V (23 vs. 36 and 36) (**Supplementary Table 4**) (i.e., the FAD-mutant enzymes had more contact with the corresponding APP residues P1’, P2’, and P3’). Furthermore, the APP helical domain tilted less in the “Active” WT state than in the other low-energy conformations, including the “Active” P117L and “Active” L286V (**Figure 2d** and **Supplementary Figure 6**). Nevertheless, it was worth noting that the  $\beta$ 3 strand of APP was formed in all three “Active” low-energy conformations (WT, P117L, and L286V), being consistent with previous studies<sup>22,43,51,52</sup>.

We showed that flexibility of the active site played an important role in  $\gamma$ -secretase activation for  $\epsilon$  cleavage of APP. Even for PS1 FAD mutants such as P117L and L286V where the “Active” low-energy conformational state was identified, the conformational space of the active site in PS1 shrunk noticeably with respect to both D257–D385 and D385–L49 distances relative to WT  $\gamma$ -secretase. In particular, the distance range between PS1 residues D257 and D385

decreased to  $\sim$ 5–11 Å and  $\sim$ 3–11 Å in the P117L and L286 PS1 mutants, respectively, while the range for D385–L49 distance shrunk to  $\sim$ 2–7 Å in both FAD mutants (**Figure 1e** and **1j**). These two PS1 FAD mutants sampled only two stable low-energy conformational states, including “Active” and “I2” (**Figure 6c**). Even in their respective “Active” states, the active site in PS1 and bound APP substrate were restricted, evidenced by the total number of interacting residues constituting the S1’, S2’, and S3’ subpockets. In addition, the P117L and L286V PS1 mutants sampled the “I2” state, in which the active site appeared “semi-closed”, with the two catalytic aspartates moving close to each other (**Figures 1e**, **1j**, and **6c**). Here, a “semi-closed” active site is defined as having a  $\sim$ D257–D385 distance between  $\sim$ 6–6.5 Å<sup>26</sup>. Furthermore, the free energy landscape near “I2” in the L286V PS1 FAD mutant complex could extend to  $\sim$ 4 Å D257–D385 distance (**Figure 1j**). A distance of  $\sim$ 4 Å between D257 – D385 signified a closed active site, in which a hydrogen bond was formed between the two catalytic aspartates (as in the “Inhibited” low-energy conformation and 5FN2<sup>33</sup> PDB structure) (**Figure 3a**). This observation supported our experimental finding that L286V showed a lower proteolytic activity compared to P117L (**Figure 1b**), as it was more effective in closing the active site to APP.

The I143T PS1 FAD mutant sampled four intermediate low-energy conformational states in its free energy profile, including the “I2”, “I3”, “I4”, and “I5” (**Figure 1f**). In the “I2” and “I4” states, the distance between two catalytic aspartates remained at  $\sim$ 6 Å, while the D385–L49 distance could be either  $\sim$ 6–7 Å in “I2” or  $\sim$ 10–11 Å in “I4” (**Figure 1f**). The presence of these two conformations in its free energy profile indicated that I143T had the ability to “semi-close” the PS1 active site, preventing the APP substrate from being properly located for its  $\epsilon$  cleavage. In the “I3” and “I5” states, the distance between PS1 residues D257 and D385 stayed at  $\sim$ 8.5–10 Å, while the D385–L49 distance could be either  $\sim$ 5–7 Å in the “I3” and  $\sim$ 2–4 Å in the “I5”. As

described in the Results section (**Figure 4b**), a hydrogen bond could be formed between the protonated oxygen atom of D385 and carbonyl group of L49, but the two catalytic aspartates were too far apart to recruit a water molecule to carry out the  $\epsilon$  cleavage. As such, this FAD mutant appeared to disrupt the D257 and D385 distance. Therefore, the I143T PS1 FAD mutant could either prevent the APP substrate from aligning within the active site (illustrated in “I2”, “I3”, and “I4” states) or disrupt the catalytic aspartate distances (shown in “I3” and “I5”) (**Figure 6e**).

The free energy landscapes of the active subpocket in the remaining PS1 FAD mutants, including L166P (**Figure 1g**), G384A (**Figure 1h**), and L435F (**Figure 1i**), all shrunk noticeably compared to WT  $\gamma$ -secretase, showing that the APP-bound active site in PS1 was more restricted in these three FAD mutants. Three intermediate low-energy conformational states were identified from the free energy profiles of the L166P PS1 FAD mutant, including “I2”, “I3”, and “I5”. As described above, the presence of “I2” and “I3” states suggested that the FAD mutant prevented the APP substrate from entering the active site, while the presence of “I3” and “I5” states suggested that this mutant increased the D257–D385 distance. However, given the relative lower free energy of “I5” compared to “I2” and “I3” (**Figure 1g**), the primary effect of the L166P FAD mutant appeared to be disrupting the D257 and D385 distance (**Figures 1g and 6g**). The primary effect of the L435F PS1 FAD mutant was similar to that of the L166P as its free energy profile sampled mostly the “I3” state, which extended towards the “I5” state (**Figure 1i**). This was to be expected as residue L435 in PS1 is located between the two catalytic aspartates D257 and D385. Its mutation to a larger residue such as phenylalanine could create steric clashes within the PS1 active site, thereby increasing the D257–D385 distance<sup>26</sup> (**Figure 6f**). This finding was consistent with that by Chen and Zacharias<sup>26</sup>, even though their simulations were performed on apo  $\gamma$ -secretase. Chen and Zacharias found that mutation of L435, which was located in close proximity to the active site,

to phenylalanine shifted the D257-D385 C $\gamma$ -distance to larger distances and increased the equilibrium C $\gamma$ -C $\gamma$  distance by 0.3 Å<sup>26</sup>. While our conclusions were identical, the effect could be observed much more clearly with GaMD: the L435F mutation increased the average C $\gamma$ -C $\gamma$  distance from 7.3 ± 1.9 Å in WT  $\gamma$ -secretase to 9.1 ± 1.2 Å in the L435F PS1 FAD mutant. Furthermore, notable changes in the conformational spaces of PS1-APP interactions were found in all six PS1 FAD mutants, which were consistent with previous experimental and computational results<sup>10,13,14,16-18,26</sup>.

The G384A PS1 mutant was the only exception where no stable “Active” low-energy conformational state was sampled even though biochemical experiments showed that this FAD mutant should have similar proteolytic activity to the L286V PS1 FAD mutant (**Figure 1b** and **1h**). Given the immediate adjacent location of G384 to the protonated catalytic aspartate D385, its mutation to a slightly larger residue (glycine to alanine) was expected to disrupt the interaction between PS1 residue D385 and APP residue L49 and even increase the D257–D385 distance. The “I2” and “I3” low-energy conformational states were identified in the free energy profile of the G384A mutant (**Figure 6d**). The mutant also sampled the “Active” conformation with hydrogen bond formed between PS1 residue D385 and APP residue L49 and ~7–8 Å distance between the PS1 catalytic aspartates, although its probability was not high enough to appear as a low-energy state. The discrepancy here could result from potential inaccuracy of the force field parameters and/or still insufficient sampling of the large enzyme-substrate complex. Moreover, as the pKa value of D257 was reasonably close to that of D385 (7.95 vs. 8.80) (**Supplementary Table 2**), there could be possible proton exchange between the two catalytic aspartates that could not yet be simulated. Furthermore, we could not determine the A $\beta$ 49/A $\beta$ 48 ratio quantitatively from the GaMD simulations in this study. While the ratio of AICD50-99 of AICD49-99 was measured at

$\sim 1.1 \pm 0.1$  from MS experiments of the WT APP-bound  $\gamma$ -secretase (**Figure 1**), the ratio between A $\beta$ 49 and A $\beta$ 48 produced from WT APP-bound  $\gamma$ -secretase in natural cell lines is  $\sim 7:3^{55}$ . Nevertheless, the experiments were still proceeded as our focus was to determine the relative differences in the quantities of AICD produced between WT and PS1 FAD mutants. We also mainly examined GaMD free energy profiles between the WT and FAD mutants of PS1.

In conclusion, we have presented the dynamic models for cleavage of amyloid precursor protein (APP) by PS1 FAD mutants of  $\gamma$ -secretase, which were consistent with mass spectrometry (MS) and western blotting biochemical experiments. Our findings were also in good agreement with Chen et al. and others<sup>17,18,22,26,43,51,52</sup>, even though the effects were clearer due to the enhanced sampling power of GaMD. First, we found that the PS1 FAD mutants confined the active site in PS1 and APP substrate. Second, the PS1 FAD mutants were found to reduce  $\gamma$ -secretase proteolytic activity by hindering APP residue L49 from proper orientation in the active site and/or disrupting the distance between the catalytic aspartates. Our findings here provided mechanistic insights into how PS1 FAD mutants affect structural dynamics and enzyme-substrate interactions of  $\gamma$ -secretase and APP.

## Materials and Methods

### C100-FLAG purification

*E. coli* BL21 cells were grown shaking in LB media at 37°C until OD<sub>600</sub> reached 0.6. Cells were induced with 0.5 mM IPTG and were grown for 4 hours. The cells were collected by centrifugation and resuspended in 50 mM HEPES pH 8, 1% Triton X-100. The cell suspension was passed through French press to lyse the cells and the lysate was incubated with anti-FLAG M2-agarose

beads from SIGMA. Bound substrates were then eluted from the beads with 100 mM Glycine pH 2.5, 0.25% NP-40 detergent and then neutralized with Tris HCl prior to being stored at -80 °C.

### **Generation of tetracistronic $\gamma$ -secretase FAD mutant constructs**

Four monocistronic pMLINK vectors, each encoding one of the  $\gamma$ -secretase components (pMLINK-PS1, pMLINK-Aph1, pMLINK-NCT and pMLINK-Pen-2), were obtained courtesy of Prof. Yigong Shi (Tsinghua University, Beijing, China). Monocistronic pMLINK-PS1 vector was mutated using Platinum™ Superfi II mutagenesis kit (Invitrogen). All constructs were verified by sequencing by ACGT. Each vector had LINK1 and LINK2 sequence flanking the gene of interest. LINK1 contains Pac1 restriction site and LINK2 has PacI and Swa1 restriction site. Mutated monocistronic pMLINK-PS1 vector was treated with restriction enzyme Pac1 to release the gene of interest (PS1). Similarly, pMLINK-APh1 was treated with SwaI restriction enzyme to linearize the vector. The released PS1 from PacI digestion was inserted into linearized pMLINK-Aph1 by ligation independent cloning (LIC) to create bicistronic pMLINK-Aph1-PS1. Similarly, bicistronic pMLINK-Pen2-Nicatrin was created using LIC method. Finally, the two bicistronic vectors were used to make the final tetacistronic vector (pMLINK-PEN-2-nicastrin-APH-1-PS1) by LIC method.

### **$\gamma$ -secretase expression and purification**

$\gamma$ -secretase was expressed in HEK 395F cells by transfection with tetracistronic WT and FAD mutant pMLINK vector. For transfection, HEK 393F cells were grown in unsupplemented Freestyle 293 media (Life Technologies, 12338-018) until cell density reached  $2 \times 10^6$  cells/ml. 150 mg of vector was mixed with 450 mg of 25 kDa linear polyethyleimines (PEI) and incubated for

30 min at room temperature. The DNA-PEI mixtures were added to HEK cells and cells were grown for 60 h. The cells were harvested, and  $\gamma$ -secretase was purified as described previously<sup>56</sup>.

### **In vitro $\gamma$ -secretase assay and immunoblotting of AICD products**

30 nM of WT or FAD mutant  $\gamma$ -secretase was preincubated for 30 min at 37 °C in assay buffer composed of 50 mM HEPES pH 7.0, 150 mM NaCl, and 0.25% 3-[(3-cholamidopropyl) dimethylammonio]-2-hydroxy-1-propanesulfonate (CHAPSO), 0.1% phosphatidylcholine and 0.025% phosphatidylethanolamine. Reactions were initiated by addition of purified 3 mM C100-FLAG substrate<sup>57</sup> and incubated at 37 °C for 16 h. The reactions were stopped by flash freezing in liquid nitrogen and stored at -20 °C. Stored  $\gamma$ -secretase reaction mixtures and C100-FLAG standards were subjected to SDS-PAGE on 4-12% bis-tris gels and transferred to PVDF membranes. Membranes were blocked with 5% dry milk for 1 h at ambient temperature and treated with anti-Flag M2 antibodies (SIGMA) for 16 h at 4 °C. Then the blot was washed and incubated with anti-mouse secondary antibodies for 1 h at ambient temperature. The membrane was washed and imaged for chemiluminescence, and bands were analyzed by densitometry.

### **Detection of AICD species**

AICD-FLAG produced from the enzymatic assay were isolated by immunoprecipitation with anti-FLAG M2 beads (SIGMA) in 10 mM MES pH 6.5, 10 mM NaCl, 0.05% DDM detergent for 16 hours at 4 °C. AICD products were eluted from the anti-FLAG beads with acetonitrile:water (1:1) with 0.1% trifluoroacetic acid. The elutes were run on a Bruker autotoflex MALDI-TOF mass spectrometer.

## Simulation system setup

The cryo-EM structure of APP-bound  $\gamma$ -secretase (PDB: 6IYC)<sup>36</sup> was used to prepare the simulation systems. Two artificial disulfide bonds between C112 of PS1-Q112C and C4 of PS1-V24C were removed as the WT residues (Q112 and V24) were restored. Five unresolved residues at the N-terminus of APP substrate C83 were added through homology modeling by SWISS-MODEL<sup>58</sup>. The large missing hydrophilic loop that connected TM6a and TM7 was not modelled as in our previous studies<sup>30,31</sup>, which had no noticeable effects on our final results. In fact, the large missing hydrophilic portion that connects TM6a and TM7 is missing in the cryo-EM structure<sup>36</sup>, but this region is not conserved and does not contain sites of PS1 FAD mutations. Moreover, Gopal Thinakaran's lab demonstrated years ago that this region is unnecessary for presenilin proteolytic function<sup>59</sup>. This is in contrast to the hydrophobic region of loop 6, which is conserved, critical for function and a domain with many PS1 FAD mutations<sup>59</sup>. The autoproteolytic cleavage of this loop upon assembly of presenilin with the other components of the  $\gamma$ -secretase complex results in the functional protease. The hydrophobic portion of the cleaved loop 6 becomes the TM6a region that is folded into the structure of  $\gamma$ -secretase<sup>36</sup>. The hydrophilic region, now the N-terminus of the presenilin CTF subunit generated by autoproteolysis, is not visible by cryo-EM, even with bound substrate, presumably because it is unstructured and not folded into the active protease complex<sup>36</sup>. The starting structure of WT APP-bound  $\gamma$ -secretase was provided in **Supplementary Data 1**. Selected PS1 FAD mutations, including P117L, I143T, L166P, G384A, L435F, and L286V (**Figure 1a**), were computationally generated using the *Mutation* function of CHARMM-GUI<sup>60-66</sup>. Furthermore, residue D385 in PS1 was protonated to simulate  $\gamma$ -secretase activation for  $\epsilon$  cleavage of APP based on the results of PROPKA3 calculations<sup>53,54</sup> (**Supplementary Table 1**). All chain termini were capped with neutral patches (acetyl and methylamide). The enzyme-substrate

complexes were embedded in POPC membrane lipid bilayers and then solvated in 0.15 M NaCl solutions using the CHARMM-GUI webserver<sup>60,62-67</sup>.

### Simulation protocols

The CHARMM36m force field parameter set<sup>68</sup> was used for the protein and lipids. The simulation systems were initially energetically minimized for 5000 steps using the steepest-descent algorithm and equilibrated with the constant number, volume, and temperature (NVT) ensemble at 310 K. They were further equilibrated for 375 ps at 310 K with the constant number, pressure, and temperature (NPT) ensemble. Short cMD simulations were then performed for 10 ns using the NPT ensemble with constant surface tension at 1 atm pressure and 310 K temperature. GaMD implemented in the GPU version of AMBER 20<sup>27,69</sup> was applied to simulate the effects of PS1 FAD mutations on  $\gamma$ -secretase activation for  $\epsilon$  cleavage of APP. The simulations involved an initial short cMD of 15 ns to calculate GaMD acceleration parameters and GaMD equilibration of added boost potentials for 60 ns. Three 1,000-1,500ns independent all-atom dual-boost GaMD production simulations with randomized initial atomic velocities were performed on the APP-bound  $\gamma$ -secretase complexes, with the reference energy set to lower bound. The upper limits of the boost potential standard deviations,  $\sigma_{0P}$  and  $\sigma_{0D}$ , were set to 6.0 kcal/mol for both dihedral and total potential energetic terms. The GaMD simulations are summarized in **Supplementary Table 2**.

### Simulation analysis

The simulation trajectories were analyzed using VMD<sup>70</sup> and CPPTRAJ<sup>38</sup>. The distance between C $\gamma$  atoms of catalytic aspartates PS1-D257 and D385 and distance between PS1 residue D385

(atom OD2) and APP residue L49 (atom O) were calculated. The *PyReweighting*<sup>28</sup> toolkit was applied for free energy calculations from the D257 – D385 and D385 – L49 distances for each system (**Figure 1**). A bin size of 1Å and cutoff of 500 frames in each bin was used to calculate the two-dimension (2D) potential mean force (PMF) free energy profiles. The time courses of APP secondary structures were calculated by CPPTRAJ<sup>38</sup>. Simulation frames were saved every 1 ps. The hierarchical agglomerative structural clustering algorithm in CPPTRAJ<sup>38</sup> was performed on GaMD simulations of WT, P117L, I143T, L166P, G384A, L435F, and L286V PS1 FAD mutant APP-bound  $\gamma$ -secretase to identify representative poses for low-energy conformational states (**Supplementary Data 1**).

## **Data Availability**

Data supporting the findings of this study are included in the article and its Supplementary Information and Data files.

## **Code Availability**

This study utilized the standard builds of the simulation software AMBER 20 (<https://ambermd.org>) according to best practices for running GaMD simulations<sup>27</sup> with all parameters specified in the Methods section.

## **Acknowledgements**

This work used supercomputing resources with allocation award TG-MCB180049 through the Extreme Science and Engineering Discovery Environment (XSEDE), which is supported by National Science Foundation grant number ACI-1548562, and project M2874 through the National

Energy Research Scientific Computing Center (NERSC), which is a U.S. Department of Energy Office of Science User Facility operated under Contract No. DE-AC02-05CH11231, and the Research Computing Cluster at the University of Kansas. This work was supported in part by the startup funding in the College of Liberal Arts and Sciences at the University of Kansas and award 2121063 from National Science Foundation (Y.M.) and AG66986 from the National Institutes of Health (M.S.W.).

### **Author Contributions**

H.N.D. performed GaMD simulations, analyzed simulation data and wrote the manuscript. S.D. performed mutagenesis, western blotting and mass spectrometry experiments and wrote the manuscript. A.B. interpreted data. Y.M. and M.S.W. supervised the project, interpreted data and wrote the manuscript. All authors contributed towards the final version of the manuscript.

### **Competing Interests**

The authors declare no competing interests

### **References**

- 1 Wolfe, M. S. & Miao, Y. Structure and mechanism of the gamma-secretase intramembrane protease complex. *Current Opinion in Structural Biology* **74**, 102373 (2022).
- 2 Bai, X. C. *et al.* An atomic structure of human gamma-secretase. *Nature* **525**, 212-217, doi:10.1038/nature14892 (2015).
- 3 Kopan, R. & Ilagan, M. X. G.  $\gamma$ -Secretase: proteasome of the membrane? *Nature Reviews Molecular Cell Biology* **5**, 499-504 (2004).
- 4 Guner, G. & Lichtenthaler, S. F. The substrate repertoire of gamma-secretase/presenilin. *Seminars in Cell & Developmental Biology* **105**, 27-42 (2020).
- 5 Wolfe, M. S. *et al.* Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. *Nature* **398**, 513-517 (1999).
- 6 Wolfe, M. Structure and Function of the gamma-Secretase Complex. *Biochemistry* **58**, 2953 (2019).

7 Tanzi, R. E. The Genetics of Alzheimer Disease. *Cold Spring Harbor Perspectives in Medicine* **2**, a006296 (2012).

8 Saura, C. *et al.* Loss of Presenilin Function Causes Impairments of Memory and Synaptic Plasticity Followed by Age-Dependent Neurodegeneration *Neuron* **42**, 1 (2004).

9 Shen, J. & Kelleher III, R. The presenilin hypothesis of Alzheimer's disease: Evidence for a loss-of-function pathogenic mechanism. *PNAS* **104**, 403-409 (2007).

10 Dehury, B., Somavarapu, A. & Kepp, K. A computer-simulated mechanism of familial Alzheimer's disease: Mutations enhance thermal dynamics and favor looser substrate-binding to gamma-secretase. *Journal of Structural Biology* **212**, 107648 (2020).

11 Eisenberg, D. & Jucker, M. The Amyloid State of Proteins in Human Diseases. *Cell* **148**, 1188-1203 (2012).

12 Selkoe, D. & Hardy, J. The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Molecular Medicine* **8**, 595-608 (2016).

13 Quintero-Monzon, O. *et al.* Dissociation between the processivity and total activity of gamma-secretase: implications for the mechanism of Alzheimer's disease-causing presenilin mutations. *Biochemistry* **50**, 9023-9035 (2011).

14 Fernandez, M., Klutkowski, J., Freret, T. & Wolfe, M. Alzheimer presenilin-1 mutations dramatically reduce trimming of long amyloid beta-peptides (Abeta) by gamma-secretase to increase 42-to-40-residue Abeta. *Journal of Biological Chemistry* **289**, 31043-31052 (2014).

15 Devkota, S., Williams, T. D. & Wolfe, M. S. Familial Alzheimer's disease mutations in amyloid protein precursor alter proteolysis by  $\gamma$ -secretase to increase amyloid  $\beta$ -peptides of  $\geq 45$  residues. *Journal of Biological Chemistry* **296**, 100281 (2021).

16 Iwatsubo, T. *et al.* Visualization of Abeta 42(43) and Abeta 40 in senile plaques with end-specific Abeta monoclonals: evidence that an intially deposited species is Abeta 42(43). *Neuron* **13**, 45-53 (1994).

17 Sun, L., Zhou, R., Yang, G. & Shi, Y. Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of Abeta42 and Abeta40 peptides by gamma-secretase. *PNAS* **114**, E476-E485 (2016).

18 Trambauer, J. *et al.* Ab43-producing PS1FAD mutants causealtered substrate interactions and respond toc-secretase modulation. *EMBO reports* **21**, e47996 (2020).

19 Karplus, M. & McCammon, J. A. Molecular dynamics simulations of biomolecules. *Nature Structural and Molecular Biology* **9**, 646-652 (2002).

20 Kong, R., Chang, S., Xia, W. & Wong, S. T. C. Molecular dynamics simulation study reveals potential substrate entry path into  $\gamma$ -secretase/presenilin-1. *Journal of Structural Biology* **191**, 120-129 (2015).

21 Hitzenberger, M. *et al.* The dynamics of  $\gamma$ -secretase and its substrates. *Seminars in Cell & Developmental Biology* **105**, 86-101 (2020).

22 Mehra, R. & Kepp, K. P. Understanding familial Alzheimer's disease: The fit-stray-trim mechanism of  $\gamma$ -secretase. *WIREs Computational Molecular Science* **12**, 1556 (2021).

23 Aguayo-Ortiz, R., Chávez-García, C., Straub, J. E. & Dominguez, L. Characterizing the structural ensemble of  $\gamma$ -secretase using a multiscale molecular dynamics approach. *Chemical Science* **8**, 5576-5584 (2017).

24 Northrop, D. B. Follow the Protons: A Low-Barrier Hydrogen Bond Unifies the Mechanisms of the Aspartic Proteases. *Accounts of Chemical Research* **34**, 790-797 (2001).

25 Hitzenberger, M. & Zacharias, M.  $\gamma$ -Secretase Studied by Atomistic Molecular Dynamics Simulations: Global Dynamics, Enzyme Activation, Water Distribution and Lipid Binding. *Frontiers in Chemistry* **6** (2019).

26 Chen, S.-Y. & Zacharias, M. How Mutations Perturb gamma-Secretase Active Site Studied by Free Energy Simulations. *ACS Chemical Neuroscience* **11**, 3321-3332 (2020).

27 Miao, Y., Feher, V. A. & McCammon, J. A. Gaussian accelerated molecular dynamics: unconstrained enhanced sampling and free energy calculation. *Journal of Chemical Theory and Computation* **11**, 3584-3595 (2015).

28 Miao, Y. *et al.* Improved reweighting of accelerated molecular dynamics simulations for free energy calculation. *Journal of Chemical Theory and Computation* **10**, 2677-2689 (2014).

29 Wang, J. *et al.* Gaussian accelerated molecular dynamics: principles and applications. *WIREs Computational Molecular Science*, e1521, doi:10.1002/wcms.1521 (2021).

30 Bhattacharai, A., Devkota, S., Bhattacharai, S., Wolfe, M. S. & Miao, Y. Mechanisms of gamma-secretase activation and substrate processing. *ACS Central Science* **6**, 969-983 (2020).

31 Bhattacharai, A. *et al.* Mechanism of Tripeptide Trimming of Amyloid beta-Peptide 49 by gamma-Secretase. *Journal of American Chemical Society* **144**, 6215-6226 (2022).

32 Takami, M. *et al.*  $\gamma$ -Secretase: Successive Tripeptide and Tetrapeptide Release from the Transmembrane Domain of  $\beta$ -Carboxyl Terminal Fragment. *Journal of Neuroscience* **29**, 13042-13052 (2009).

33 Bai, X. C., Rajendra, E., Yang, G., Shi, Y. & Scheres, S. H. Sampling the conformational space of the catalytic subunit of human gamma-secretase. *eLife*, 11182 (2015).

34 Sun, L. *et al.* Structural Basis of Human Gamma-Secretase Assembly. *Proc Natl Acad Sci USA* **112**, 6003 (2015).

35 Yang, G. *et al.* Structural basis of Notch recognition by human gamma-secretase. *Nature* **565**, 192-197 (2019).

36 Zhou, R. *et al.* Recognition of the amyloid precursor protein by human gamma-secretase. *Science* **363**, aaw0930 (2019).

37 Yang, G. *et al.* Structural basis of gamma-secretase inhibition and modulation by small molecule drugs. *Cell* **184**, 521-533.e514 (2021).

38 Roe, D. R. & Cheatham, I. T. E. PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data. *Journal of Chemical Theory and Computation* **9**, 3084-3095 (2013).

39 Moehlmann, T. *et al.* Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on A $\beta$ 42 production. *PNAS* **99**, 8025-8030 (2002).

40 Heilig, E. A., Xia, W., Shen, J. & Kelleher III, R. J. A Presenilin-1 Mutation Identified in Familial Alzheimer Disease with Cotton Wool Plaques Causes a Nearly Complete Loss of  $\gamma$ -Secretase Activity. *Journal of Biological Chemistry* **285**, 22350-22359 (2010).

41 Nakaya, Y. *et al.* Random Mutagenesis of Presenilin-1 Identifies Novel Mutants Exclusively Generating Long Amyloid  $\beta$ -Peptides. *Journal of Biological Chemistry* **280**, 19070-19077 (2005).

42 Somavarapu, A. K. & Kepp, K. P. Loss of stability and hydrophobicity of presenilin 1 mutations causing Alzheimer's disease. *Journal of Neurochemistry* **137**, 101-111 (2016).

43 Somavarapu, A. K. & Kepp, K. P. Membrane dynamics of  $\gamma$ -secretase provides a molecular basis for beta-amyloid binding and processing. *ACS Chemical Neuroscience* **8**, 2424-2436 (2017).

44 Okochi, M. *et al.*  $\gamma$ -secretase modulators and presenilin 1 mutants act differently on presenilin/ $\gamma$ -secretase function to cleave A $\beta$ 42 and A $\beta$ 43 *Cell Reports* **3**, 42-51 (2013).

45 Szaruga, M. *et al.* Alzheimer's-Causing Mutations Shift A $\beta$  Length by Destabilizing  $\gamma$ -Secretase-A $\beta$ n Interactions *Cell* **170**, 443-456 (2017).

46 Heilig, E. A., Xia, W., Shen, J. & Kelleher, R. J. r. A presenilin-1 mutation identified in familial Alzheimer disease with cotton wool plaques causes a nearly complete loss of gamma-secretase activity. *Journal of Biological Chemistry* **285**, 22350-22359 (2010).

47 Kretner, B. *et al.* Generation and deposition of A $\beta$ 43 by the virtually inactive presenilin-1 L435F mutant contradicts the presenilin loss-of-function hypothesis of Alzheimer's disease. *EMBO Molecular Medicine* **8**, 458-465 (2016).

48 Veugelen, S., Saito, T., Saido, T. C., Chávez-Gutiérrez, L. & Strooper, B. D. Familial Alzheimer's Disease Mutations in Presenilin Generate Amyloidogenic A $\beta$  Peptide Seeds *Neuron* **90**, 410-416 (2016).

49 Chávez-Gutiérrez, L. *et al.* The mechanism of  $\gamma$ -Secretase dysfunction in familial Alzheimer disease. *The EMBO Journal* **31**, 2261-2274 (2012).

50 Lu, X. & Huang, J. A thermodynamic investigation of amyloid precursor protein processing by human gamma-secretase. *Communications Biology* **5**, 837 (2022).

51 Somavarapu, A. K. & Kepp, K. P. The dynamic mechanism of presenilin-1 function: sensitive gate dynamics and loop unplugging control protein access. *Neurobiology of Disease* **89**, 147-156 (2016).

52 Dehury, B., Tang, N., Mehra, R., Blundell, T. L. & Kepp, K. P. Side-by-side comparison of notch- and C83 binding to  $\gamma$ -secretase in a complete membrane model at physiological temperatures. *RSC Advances* **10**, 31215-31232 (2020).

53 Sondergaard, C. R., Olsson, M. H. M., Rostkowsi, M. & Jensen, J. H. Improved Treatment of Ligands and Coupling Effects in Empirical Calculations and Rationalization of pKa values. *Journal of Chemical Theory and Computation* **7**, 2284-2295 (2011).

54 Olsson, M. H. M., Sondergaard, C. R., Rostkowsi, M. & Jensen, J. H. PROPKA3: consistent treatment of internal and surface residues in empirical pKa predictions. *Journal of Chemical Theory and Computation* **7**, 525-537 (2011).

55 Sato, T. *et al.* Potential link between amyloid beta-protein 42 and C-terminal fragment beta 49-99 of beta-amyloid precursor protein. *Journal of Biological Chemistry* **278**, 24294-24301 (2003).

56 Bolduc, D. M., Montagna, D. R., Seghers, M. C., Wolfe, M. S. & Selkoe, D. J. The amyloid-beta forming tripeptide cleavage mechanism of gamma-secretase. *eLife*, 17578 (2016).

57 Li, Y.-M. *et al.* Presenilin-1 is linked with  $\gamma$ -secretase activity in the detergent solubilized state. *PNAS* **97**, 6138-6143 (2000).

58 Waterhouse, A. *et al.* SWISS-MODEL: homology modelling of protein structures and complexes. *Nucleic Acids Research* **46**, W296-W303 (2018).

59 Saura, C. A. *et al.* The Nonconserved Hydrophilic Loop Domain of Presenilin (PS) Is Not Required for PS Endoproteolysis or Enhanced A $\beta$ 42 Production Mediated by Familial Early Onset Alzheimer's Disease-linked PS Variants\*. *Journal of Biological Chemistry* **275**, 17136-17142 (2000).

60 Jo, S., Kim, T., Iyer, V. & Im, W. CHARMM-GUI: A Web-based Graphical User Interface for CHARMM. *Journal of Computational Chemistry* **29**, 1859-1865 (2008).

61 Brooks, B. *et al.* CHARMM: The Biomolecular Simulation Program. *Journal of Computational Chemistry* **30**, 1545-1614 (2009).

62 Lee, J. *et al.* CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM Simulations using the CHARMM36 Additive Force Field. *Journal of Chemical Theory and Computation* **12**, 405-413 (2016).

63 Wu, E. *et al.* CHARMM-GUI Membrane Builder Toward Realistic Biological Membrane Simulations. *Journal of Computational Chemistry* **35**, 1997-2004 (2014).

64 Jo, S., Lim, J., Klauda, J. & Im, W. CHARMM-GUI Membrane Builder for Mixed Bilayers and Its Application to Yeast Membranes. *Biophysical Journal* **97**, 50-58 (2009).

65 Jo, S., Kim, T. & Im, W. Automated Builder and Database of Protein/Membrane Complexes for Molecular Dynamics Simulations. *PLoS ONE* **2**, e880 (2007).

66 Lee, J. *et al.* CHARMM-GUI Membrane Builder for Complex Biological Membrane Simulations with Glycolipids and Lipoglycans. *Journal of Chemical Theory and Computation* **15**, 775-786 (2019).

67 Lee, J. *et al.* CHARMM-GUI supports the Amber force fields. *Journal of Chemical Physics* **153**, 035103 (2020).

68 Huang, J. *et al.* CHARMM36m: an improved force field for folded and intrinsically disordered proteins. *Nature Methods* **14**, 71-73 (2017).

69 Salomon-Ferrer, R., Gotz, A. W., Poole, D., Le Grand, S. & Walker, R. C. Routined microsecond molecular dynamics simulations with AMBER on GPUs. 2. Explicit solvent Particle Mesh Ewald. *Journal of Chemical Theory and Computation* **9**, 3878-3888 (2013).

70 Humphrey, W., Dalke, A. & Schulten, K. VMD: visual molecular dynamics. *Journal of Molecular Graphics and Modelling* **14**, 33-38 (1996).

## Figure captions

**Figure 1. Summary of effects of PS1 FAD mutations on enzyme-substrate interactions of the APP bound  $\gamma$ -secretase complex.** (a) Cryo-EM structure of  $\gamma$ -secretase complex with APP bound (PDB: 6IYC) and locations of six PS1 FAD mutation residues (red spheres). The four components of  $\gamma$ -secretase are Nicastrin (NCT, green), Presenilin-1 (PS1, teal), Aph-1 (yellow) and Pen-2 (magenta). APP is shown in orange. (b) Anti-FLAG immunoblots and quantification of total AICD (black), AICD50-99 (red), and AICD49-99 (blue)-FLAG levels generated from the  $\epsilon$  cleavage of APP by the WT and FAD mutants of  $\gamma$ -secretase by densitometry. Purified C100-FLAG at a range of known concentrations was used to generate a standard curve. (c) MALDI-TOF MS detection of AICD50-99 and AICD49-99 products generated from the  $\epsilon$  cleavage of APP by the WT and PS1 FAD mutants of  $\gamma$ -secretase. T-tests were performed, and the resulting p values were added along with the ratios to highlight the significance of the ratios determined for the PS1 FAD mutants. (d-j) 2D free energy profiles of the distance between PS1 residues D257 (atom C $\gamma$ ) and D385 (atom C $\gamma$ ) and distance between PS1 residue D385 (protonated oxygen) and APP residue L49 (carbonyl oxygen) in the WT (d) and P117L (e), I143T (f), L166P (g), G384A (h), L435F (i), and L286V (j) FAD mutants of APP bound  $\gamma$ -secretase. The low-energy conformational states are labeled “Active”, “Inhibited”, and “I1”–“I5”.

**Figure 2. The “Active” low-energy conformational state in the WT, L286V, and P117L PS1 FAD mutants of APP-bound  $\gamma$ -secretase.** (a) The “Active” conformation of the APP-bound PS1 in WT (green), L286V (red), and P117L (blue) systems. (b) Active site of APP-bound PS1 in the “Active” WT, L286V, and P117L PS1. The distances between PS1 residues D257 and D385 are  $\sim$ 7.0 Å,  $\sim$ 7.0 Å,  $\sim$ 7.4 Å, and the distances between PS1 residue D385 and APP residue L49 are  $\sim$ 3.0 Å,  $\sim$ 2.9 Å,  $\sim$ 2.7 Å in the “Active” WT, L286V, and P117L  $\gamma$ -secretase, respectively. (c)

Conformations of TM6a, TM7, and APP in the “Active” WT, L286V, and P117L PS1. **(d)** Conformations of the APP substrate in the “Active” WT, L286V, and P117L PS1. **(e)** Locations of APP substrate residues P1’, P2’, and P3’ in the “Active” WT, L286V, and P117L PS1.

**Figure 3. Distinct low-energy conformational states of catalytic aspartates and enzyme-substrate interactions at the active site of WT and PS1 FAD mutant  $\gamma$ -secretase compared to “Active” WT conformation.** **(a)** The “Inhibited” state, for which the distance between PS1 residues D257 and D385 is  $\sim$ 4.1 Å, and the distance between PS1 residue D385 and APP residue L49 is  $\sim$ 12.5 Å. **(b)** The “I1” state, for which the distance between PS1 residues D257 and D385 is  $\sim$ 8.6 Å, and the distance between PS1 residue D385 and APP residue L49 is  $\sim$ 8.4 Å. **(c)** The “I2” state, for which the distance between PS1 residues D257 and D385 is  $\sim$ 6.5 Å, and the distance between PS1 residue D385 and APP residue L49 is  $\sim$ 6.5 Å. **(d)** The “I3” state, for which the distance between PS1 residues D257 and D385 is  $\sim$ 8.8 Å, and the distance between PS1 residue D385 and APP residue L49 is  $\sim$ 6.1 Å. **(e)** The “I4” state, for which the distance between PS1 residues D257 and D385 is  $\sim$ 6.2 Å, and the distance between PS1 residue D385 and APP residue L49 is  $\sim$ 11.5 Å. **(f)** The “I5” state, for which the distance between PS1 residues D257 and D385 is  $\sim$ 8.5 Å, and the distance between PS1 residue D385 and APP residue L49 is  $\sim$ 2.9 Å. The “Active” WT low-energy conformation is shown in green for reference.


**Figure 4. Comparison between the “Active” and “I5” low-energy conformational states in  $\gamma$ -secretase.** **(a)** The “Active” low-energy conformational state of WT PS1, where the distance between residues D257 and D385 is  $\sim$ 7.0 Å. A water molecule formed hydrogen bonds with the two catalytic aspartates and poised for the  $\epsilon$  cleavage of the amide bond between residues L49–V50 of APP. **(b)** The “I5” low-energy conformational state of L166P FAD mutant PS1, where the distance between the two catalytic aspartates D257 and D385 is too large at  $\sim$ 8.5 Å to trap a water

molecule for the  $\epsilon$  cleavage of APP. **(c)** Location of APP substrate residues P1', P2', and P3' in the “I5” low-energy conformational state compared to “Active” WT. The “Active” and “I5” low-energy conformational states are shown in green and blue, respectively.


**Figure 5. Time-dependent secondary structures of APP bound to  $\gamma$ -secretase calculated from the GaMD simulations.** Time courses of the APP secondary structures in the **(a)** WT (Sim1), **(b)** P117L (Sim1), **(c)** I143T (Sim1), **(d)** L166P (Sim2), **(e)** G384A (Sim3), **(f)** L435F (Sim1) and **(g)** L286V (Sim1) PS1 FAD mutant  $\gamma$ -secretase calculated from representative GaMD simulations. Results from other simulations are plotted in **Supplementary Figures 10-13**.

**Figure 6. Summary of the effects of PS1 FAD mutations on the  $\epsilon$  cleavage of APP by  $\gamma$ -secretase.** **(a)** Structural model of APP-bound PS1. The APP substrates are more tilted in the PS1 FAD mutants compared to WT  $\gamma$ -secretase. **(b)** The “Active” WT  $\gamma$ -secretase. **(c)** The active site of the L286V and P117L PS1 FAD mutants. **(d-e)** The active site of G384A (“I2”–“I3”) and I143T (“I2”–“I5”) PS1 FAD mutants. **(f-g)** The active site of the L435F (“I3”) and L166P (“I2”–“I3” and “I5”) PS1 FAD mutants.

**Figure 1**



**Figure 2**



**Figure 3**





Figure 4



**Figure 5**





Figure 6



# Supporting Information

## Effects of Presenilin-1 Familial Alzheimer's Disease Mutations on $\gamma$ -Secretase Activation for Cleavage of Amyloid Precursor Protein


**Hung N. Do<sup>1,#</sup>, Sujan Devkota<sup>2,#</sup>, Apurba Bhattacharai<sup>1</sup>, Michael S. Wolfe<sup>2,\*</sup>, and Yinglong  
Miao<sup>1,\*</sup>**

<sup>1</sup>Center for Computational Biology and Department of Molecular Biosciences; <sup>2</sup>Department of  
Medicinal Chemistry, School of Pharmacy, University of Kansas, Lawrence, Kansas 66047


<sup>#</sup> These authors contributed equally to this work

\*To whom correspondence should be addressed: [mswolfe@ku.edu](mailto:mswolfe@ku.edu) and [miao@ku.edu](mailto:miao@ku.edu)


**Figure S1.** The average C $\gamma$ -atom distances between PS1 residues D257 and D385 in the WT, P117L, I143T, L166P, G384A, L435F, and L286V PS1 FAD mutant  $\gamma$ -secretase calculated from GaMD simulations.




**Figure S2.** Time courses of distances between PS1 residues D257 (atom C $\gamma$ ) and D385 (atom C $\gamma$ ) **(A)**, PS1 residue D385 (protonated oxygen) and APP residue V50 (carbonyl oxygen) **(B)**, PS1 residue D385 (protonated oxygen) and APP L49 (carbonyl oxygen) **(C)**, PS1 residue D385 (protonated oxygen) and APP T48 (carbonyl oxygen) **(D)** in the WT  $\gamma$ -secretase.




**Figure S3.** Time courses of distances between PS1 residues D257 (atom C $\gamma$ ) and D385 (atom C $\gamma$ ) (A and B), PS1 residue D385 (protonated oxygen) and APP residue V50 (carbonyl oxygen) (C and D), PS1 residue D385 (protonated oxygen) and APP residue L49 (carbonyl oxygen) (E and F), PS1 residue D385 (protonated oxygen) and APP residue T48 (carbonyl oxygen) (G and H) in the P117L (A, C, E, and G) and L286V (B, D, F, and H) PS1 FAD mutant  $\gamma$ -secretase.




**Figure S4.** Time courses of distances between PS1 residues D257 (atom C $\gamma$ ) and D385 (atom C $\gamma$ ) (A and B), PS1 residue D385 (protonated oxygen) and APP residue V50 (carbonyl oxygen) (C and D), PS1 residue D385 (protonated oxygen) and APP residue L49 (carbonyl oxygen) (E and F), PS1 residue D385 (protonated oxygen) and APP residue T48 (carbonyl oxygen) (G and H) in the I143T (A, C, E, and G) and G384A (B, D, F, and H) PS1 FAD mutant  $\gamma$ -secretase.




**Figure S5.** Time courses of distances between PS1 residues D257 (atom C $\gamma$ ) and D385 (atom C $\gamma$ ) (A and B), PS1 residue D385 (protonated oxygen) and APP residue V50 (carbonyl oxygen) (C and D), PS1 residue D385 (protonated oxygen) and APP residue L49 (carbonyl oxygen) (E and F), PS1 residue D385 (protonated oxygen) and APP residue T48 (carbonyl oxygen) (G and H) in the L166P (A, C, E, and G) and L435F (B, D, F, and H) PS1 FAD mutant  $\gamma$ -secretase.




**Figure S6.** Intermediate low-energy conformational states of WT and PS1 FAD mutant  $\gamma$ -secretase compared to “Active” WT conformation. The “Inhibited” (A), “I1” (B), “I2” (C), “I3” (D), “I4” (E), and “I5” (F) low-energy conformational state compared to “Active” WT conformational state. The transmembrane domains 1 to 9 are labeled TM1–TM9.




**Figure S7.** Conformations of the APP substrate in the intermediate low-energy conformational states of WT and PS1 FAD mutant  $\gamma$ -secretase compared to “Active” WT conformation.




**Figure S8.** Conformations of TM6a, TM7, and APP in the intermediate low-energy conformational states of WT and PS1 FAD mutant  $\gamma$ -secretase compared to “Active” WT conformation.




**Figure S9.** Conformations of TM8 in the intermediate low-energy conformational states of WT and PS1 FAD mutant  $\gamma$ -secretase compared to “Active” WT conformation.




**Figure S10. Dynamics of the nucleophilic water molecules during the  $\epsilon$ -cleavage of APP by WT  $\gamma$ -secretase.** **(A)** Time courses of the distances between PS1 residues D257 (atom C $\gamma$ ) and D385 (atom C $\gamma$ ) (red) and PS1 residue D385 (protonated oxygen) and APP residue L49 (carbonyl oxygen). **(B)** 2D free energy profile of the distance between PS1 residues D257 (atom C $\gamma$ ) and D385 (atom C $\gamma$ ) and distance between PS1 residue D257 (atom OD1) and nucleophilic water (atom O). **(C)** 2D free energy profile of the distance between PS1 residue D257 (atom OD1) and nucleophilic water (atom O) and distance between PS1 residue D385 (atom OD1) and nucleophilic water (atom O). The 100ns GaMD simulation was carried out starting from the 1200ns checkpoint of Sim1 WT  $\gamma$ -secretase, with the coordinates of all atoms saved.




**Figure S11.** Time courses of the APP secondary structures in the WT PS1 calculated from the other two independent GaMD simulations apart from the one plotted in **Figure 5**.




**Figure S12.** Time courses of the APP secondary structures in the P117L (A-B) and L286V (C-D) PS1 calculated from the other independent GaMD simulations apart from the ones plotted in **Figure 5**.




**Figure S13.** Time courses of the APP secondary structures in the I143T (A-B) and G348A (C-D) PS1 calculated from the other independent GaMD simulations apart from the ones plotted in **Figure 5.**




**Figure S14.** Time courses of the APP secondary structures in the L166P (A-B) and L435F (C-D) PS1 calculated from the other independent GaMD simulations apart from the ones plotted in **Figure 5**.




**Figure S15.** Time courses of distances between PS1 residues D257 (atom C $\gamma$ ) and D385 (atom C $\gamma$ ) **(A)**, PS1 residue D385 (protonated oxygen) and APP residue V50 (carbonyl oxygen) **(B)**, PS1 residue D385 (protonated oxygen) and APP residue L49 (carbonyl oxygen) **(C)**, PS1 residue D385 (protonated oxygen) and APP residue T48 (carbonyl oxygen) **(D)** calculated from cMD simulations of the WT, P117L, I143T, and L166P PS1 FAD mutant  $\gamma$ -secretase.



**Figure S16.** 2D free energy profiles of the distance between PS1 residues D257 (atom C $\gamma$ ) and D385 (atom C $\gamma$ ) and distance between PS1 residue D385 (protonated oxygen) and APP residue L49 (**A-D**), V50 (**E-H**), or T48 (**I-L**) (carbonyl oxygen) calculated from the cMD simulations of the WT (**A**, **E**, and **I**), P117L (**B**, **F**, and **J**), I143T (**C**, **G**, and **K**), and L166P (**D**, **H**, and **L**) FAD mutants of APP bound  $\gamma$ -secretase. The low-energy conformational states are labeled “Active” and “I2”–“I5”.



**Figure S17.** 2D free energy profiles of the distance between PS1 residues D257 (atom C $\gamma$ ) and D385 (atom C $\gamma$ ) and distance between PS1 residue D385 (protonated oxygen) and APP residue V50 (**A-G**) or T48 (**H-N**) (carbonyl oxygen) calculated from the GaMD simulations of the WT (**A** and **H**) and P117L (**B** and **I**), I143T (**C** and **J**), L166P (**D** and **K**), G384A (**E** and **L**), L435F (**F** and **M**), and L286V (**G** and **N**) FAD mutants of APP bound  $\gamma$ -secretase. The low-energy conformational states are labeled to correspond to “Inhibited” and “I1”–“I5”.



**Table S1.** Summary of GaMD simulations performed on the APP-bound  $\gamma$ -secretase complexes, including WT, P117L, I143T, L166P, G384A, L435F, and L286V PS1 FAD mutant  $\gamma$ -secretase.

System	Method	Simulation Length (ns)	Boost Potential (kcal/mol)
WT	GaMD_Dual	3 x 1500	13.5 $\pm$ 4.3
P117L	GaMD_Dual	3 x 1500	11.3 $\pm$ 4.0
I143T	GaMD_Dual	3 x 1500	14.0 $\pm$ 4.4
L166P	GaMD_Dual	3 x 1500	14.8 $\pm$ 4.5
G384A	GaMD_Dual	3 x 1500	13.8 $\pm$ 4.4
L435F	GaMD_Dual	3 x 1500	14.0 $\pm$ 4.4
L286V	GaMD_Dual	3 x 1500	14.1 $\pm$ 4.4

**Table S2.** pKa values of D257 and D385 in the starting structure (PDB: 6IYC) and low-energy conformational states from GaMD simulations as calculated using PROPKA3<sup>1,2</sup> at pH 7.0.

System	pKa(D257)	pKa(D385)
Starting structure	8.0	8.8
“Active” (WT)	5.6	9.8
“Active” (L286V)	6.0	10.1
“Active” (P117L)	6.3	9.0
“Inhibited” (WT)	4.7	10.1
“I1” (WT)	5.6	7.1
“I2” (I143T)	5.8	8.8
“I3” (I143T)	3.6	7.8
“I4” (I143T)	5.6	7.2
“I5” (L166P)	5.0	9.6

**Table S3.** Summary of the (a) C $\gamma$ -atom distances between PS1 residues D257 and D385 and (b) C $\gamma$ -C $\beta$ -atom distances between PS1 residues D257 and A385 in the available PDB structures of  $\gamma$ -secretase on the Protein Data Bank.

PDB	Structure description on the Protein Data Bank	Year released	D257-D385 Distance (Å)
4UIS <sup>(a)</sup>	CryoEM structure of human gamma-secretase complex	2015 <sup>3</sup>	4.0
5FN5 <sup>(a)</sup>	CryoEM structure of gamma-secretase in class 3 of apo-state ensemble	2015 <sup>4</sup>	5.4
5FN2 <sup>(a)</sup>	CryoEM structure of gamma-secretase in complex with a drug DAPT	2015 <sup>4</sup>	3.9
5FN4 <sup>(a)</sup>	CryoEM structure of gamma-secretase in class 2 of the apo-state ensemble	2015 <sup>4</sup>	11.5
5FN3 <sup>(a)</sup>	CryoEM structure of gamma-secretase in class 1 of the apo-state ensemble	2015 <sup>4</sup>	5.1
5A63 <sup>(a)</sup>	CryoEM structure of human gamma-secretase complex at 3.4Å resolution	2015 <sup>5</sup>	7.2
6IDF <sup>(b)</sup>	CryoEM structure of gamma-secretase in complex with a Notch fragment	2018 <sup>6</sup>	8.6
6IYC <sup>(b)</sup>	Recognition of the amyloid precursor protein by human gamma-secretase	2019 <sup>7</sup>	9.1
6LQG <sup>(a)</sup>	Human gamma-secretase in complex with small molecule Avagacestat	2021 <sup>8</sup>	7.1
6LR4 <sup>(a)</sup>	Molecular basis for inhibition of human gamma-secretase by small molecule	2021 <sup>8</sup>	6.2
7C9I <sup>(a)</sup>	Human gamma-secretase in complex with small molecule L-685,458	2021 <sup>8</sup>	6.6
7D8X <sup>(a)</sup>	CryoEM structure of human gamma-secretase in complex with E2012 and L685458	2021 <sup>8</sup>	6.4

**Table S4.** List of amino acid residues constituting the S1', S2', and S3' subpockets in the WT “Active”, L286V “Active”, P117L “Active”, and L166P “I5” low-energy conformations of  $\gamma$ -secretase. The residues that are within 5 Å of APP substrate residues P1', P2', and P3' are listed in the table.

System	S1'	S2'		S3'		
“Active” (WT)	I287	L85 <sup>TM1</sup>	Y389 <sup>TM7</sup>	T281		
	K380	V379	T421 <sup>TM8</sup>	I287		
	L381	K380	L422 <sup>TM8</sup>	G378		
	G382	L381	L425 <sup>TM8</sup>	V379		
	D385 <sup>TM7</sup>	G382	L432	K380		
		D385 <sup>TM7</sup>	A434	L381		
“Active” (L286V)	D257 <sup>TM6</sup>	G382	L85 <sup>TM1</sup>	T421 <sup>TM8</sup>	T281	
	L268 <sup>TM6a</sup>	D385 <sup>TM7</sup>	V379	L422 <sup>TM8</sup>	L282	
	L271 <sup>TM6a</sup>	A431	K380	L425 <sup>TM8</sup>	I287	
	V272 <sup>TM6a</sup>	A434	L381	A431	V379	
	L282		G382	L432	K380	
	I287		D385 <sup>TM7</sup>	P433	L381	
	K380		Y389 <sup>TM7</sup>	A434	L425 <sup>TM8</sup>	
	L381		L418 <sup>TM8</sup>	L435	A431	
“Active” (P117L)	D257 <sup>TM6</sup>	G382	R269 <sup>TM6a</sup>	L418 <sup>TM8</sup>	R269 <sup>TM6a</sup>	K380
	L268 <sup>TM6a</sup>	D385 <sup>TM7</sup>	V272 <sup>TM6a</sup>	T421 <sup>TM8</sup>	L271 <sup>TM6a</sup>	L381
	R269 <sup>TM6a</sup>		V379	L422 <sup>TM8</sup>	V272 <sup>TM6a</sup>	G382
	L271 <sup>TM6a</sup>		K380	L425 <sup>TM8</sup>	A275 <sup>TM6a</sup>	
	V272 <sup>TM6a</sup>		L381	A434	Q276 <sup>TM6a</sup>	
	I287		G382	L435	I287	
	K380		D385 <sup>TM7</sup>	S438 <sup>TM9</sup>	G378	
	L381		Y389 <sup>TM7</sup>		V379	
“I5” (L166P)	D257 <sup>TM6</sup>		L85 <sup>TM1</sup>	Y389 <sup>TM7</sup>	I287	
	I287		V379	L418 <sup>TM8</sup>	G378	
	K380		K380	L422 <sup>TM8</sup>	V379	
	L381		L381	A434	K380	
	G382		G382	L435	L381	
	D385 <sup>TM7</sup>		D385 <sup>TM7</sup>	S438 <sup>TM9</sup>	G382	

## References

- 1 Sondergaard, C. R., Olsson, M. H. M., Rostkowsi, M. & Jensen, J. H. Improved Treatment of Ligands and Coupling Effects in Empirical Calculations and Rationalization of pKa values. *Journal of Chemical Theory and Computation* **7**, 2284-2295 (2011).
- 2 Olsson, M. H. M., Sondergaard, C. R., Rostkowsi, M. & Jensen, J. H. PROPKA3: consistent treatment of internal and surface residues in empirical pKa predictions. *Journal of Chemical Theory and Computation* **7**, 525-537 (2011).
- 3 Sun, L. *et al.* Structural Basis of Human Gamma-Secretase Assembly. *Proc Natl Acad Sci USA* **112**, 6003 (2015).
- 4 Bai, X. C., Rajendra, E., Yang, G., Shi, Y. & Scheres, S. H. Sampling the conformational space of the catalytic subunit of human gamma-secretase. *eLife*, 11182 (2015).
- 5 Bai, X. C. *et al.* An Atomic Structure of Human Gamma-Secretase. *Nature* **525**, 212 (2015).
- 6 Yang, G. *et al.* Structural basis of Notch recognition by human gamma-secretase. *Nature* **565**, 192-197 (2019).
- 7 Zhou, R. *et al.* Recognition of the amyloid precursor protein by human gamma-secretase. *Science* **363**, aaw0930 (2019).
- 8 Yang, G. *et al.* Structural basis of gamma-secretase inhibition and modulation by small molecule drugs. *Cell* **184**, 521-533.e514 (2021).